1
|
Campbell L, Fredericks J, Mathivha K, Moshesh P, Coovadia A, Chirwa P, Dillon B, Ghoor A, Lawrence D, Nair L, Mabaso N, Mokwele D, Novellie M, Krause A, Carstens N. The implementation and utility of clinical exome sequencing in a South African infant cohort. Front Genet 2023; 14:1277948. [PMID: 38028619 PMCID: PMC10665497 DOI: 10.3389/fgene.2023.1277948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Accepted: 10/23/2023] [Indexed: 12/01/2023] Open
Abstract
Genetic disorders are significant contributors to infant hospitalization and mortality globally. The early diagnosis of these conditions in infants remains a considerable challenge. Clinical exome sequencing (CES) has shown to be a successful tool for the early diagnosis of genetic conditions, however, its utility in African infant populations has not been investigated. The impact of the under-representation of African genomic data, the cost of testing, and genomic workforce shortages, need to be investigated and evidence-based implementation strategies accounting for locally available genetics expertise and diagnostic infrastructure need to be developed. We evaluated the diagnostic utility of singleton CES in a cohort of 32 ill, South African infants from two State hospitals in Johannesburg, South Africa. We analysed the data using a series of filtering approaches, including a curated virtual gene panel consisting of genes implicated in neonatal-and early childhood-onset conditions and genes with known founder and common variants in African populations. We reported a diagnostic yield of 22% and identified seven pathogenic variants in the NPHS1, COL2A1, OCRL, SHOC2, TPRV4, MTM1 and STAC3 genes. This study demonstrates the utility value of CES in the South African State healthcare setting, providing a diagnosis to patients who would otherwise not receive one and allowing for directed management. We anticipate an increase in the diagnostic yield of our workflow with further refinement of the study inclusion criteria. This study highlights important considerations for the implementation of genomic medicine in under-resourced settings and in under-represented African populations where variant interpretation remains a challenge.
Collapse
Affiliation(s)
- L. Campbell
- Division of Human Genetics, National Health Laboratory Service andSchool of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - J. Fredericks
- Department of Paediatrics and Child Health, School of Clinical Medicine, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - K. Mathivha
- Department of Paediatrics and Child Health, School of Clinical Medicine, Nelson Mandela Children’s Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - P. Moshesh
- Department of Paediatrics and Child Health, School of Clinical Medicine, Nelson Mandela Children’s Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - A. Coovadia
- Department of Paediatrics and Child Health, School of Clinical Medicine, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - P. Chirwa
- Nelson Mandela Children’s Hospital, Johannesburg, South Africa
| | - B. Dillon
- Division of Human Genetics, National Health Laboratory Service andSchool of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - A. Ghoor
- Department of Paediatrics and Child Health, School of Clinical Medicine, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - D. Lawrence
- Department of Paediatrics and Child Health, School of Clinical Medicine, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - L. Nair
- Department of Paediatrics and Child Health, School of Clinical Medicine, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - N. Mabaso
- Division of Human Genetics, National Health Laboratory Service andSchool of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - D. Mokwele
- Division of Human Genetics, National Health Laboratory Service andSchool of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - M. Novellie
- Division of Human Genetics, National Health Laboratory Service andSchool of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - A. Krause
- Division of Human Genetics, National Health Laboratory Service andSchool of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - N. Carstens
- Division of Human Genetics, National Health Laboratory Service andSchool of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- Genomics Platform, South African Medical Research Council, Cape Town, South Africa
| |
Collapse
|
2
|
Braun J, Specker C, Schulze-Koops H, Haase I, Kötter I, Hoyer B, Aringer M, Krusche M, Voormann A, Wagner U, Krause A. [Position paper of the German Society of Rheumatology e.V. (DGRh) regarding the situation of advanced training in the discipline of rheumatology in Germany]. Z Rheumatol 2023; 82:615-620. [PMID: 37335384 DOI: 10.1007/s00393-023-01349-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/27/2023] [Indexed: 06/21/2023]
Affiliation(s)
- J Braun
- Deutschen Gesellschaft für Rheumatologie e. V., Wilhelmine-Gemberg-Weg 6, 10179, Berlin, Deutschland
- c/o Praxis Dr. Karberg, Schlossstr. 110, 12163, Berlin, Deutschland
- Ruhr Universität Bochum, Bochum, Deutschland
| | - C Specker
- Deutschen Gesellschaft für Rheumatologie e. V., Wilhelmine-Gemberg-Weg 6, 10179, Berlin, Deutschland
- Klinik für Rheumatologie und Klinische Immunologie, KEM | Evangelische Kliniken Essen-Mitte gGmbH, Essen, Deutschland
| | - H Schulze-Koops
- Deutschen Gesellschaft für Rheumatologie e. V., Wilhelmine-Gemberg-Weg 6, 10179, Berlin, Deutschland
- Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, München, Deutschland
| | - I Haase
- Deutschen Gesellschaft für Rheumatologie e. V., Wilhelmine-Gemberg-Weg 6, 10179, Berlin, Deutschland
- Klinik für Rheumatologie und Hiller Forschungszentrum, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
| | - I Kötter
- Deutschen Gesellschaft für Rheumatologie e. V., Wilhelmine-Gemberg-Weg 6, 10179, Berlin, Deutschland
- Klinik für Rheumatologie und Immunologie am Klinikum Bad Bramstedt und Sektion für Rheumatologie und Entzündliche Systemerkrankungen in der III. Medizin des Universitätsklinikum Eppendorf (UKE), Hamburg, Deutschland
| | - B Hoyer
- Deutschen Gesellschaft für Rheumatologie e. V., Wilhelmine-Gemberg-Weg 6, 10179, Berlin, Deutschland
- Sektion Rheumatologie und Exzellenzzentrum für Entzündungsmedizin, Universitätsklinikum Schleswig-Holstein, Christian-Albrechts-Universität, Kiel, Deutschland
| | - M Aringer
- Deutschen Gesellschaft für Rheumatologie e. V., Wilhelmine-Gemberg-Weg 6, 10179, Berlin, Deutschland
- Abteilung Rheumatologie, Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Deutschland
| | - M Krusche
- Deutschen Gesellschaft für Rheumatologie e. V., Wilhelmine-Gemberg-Weg 6, 10179, Berlin, Deutschland
- Klinik für Rheumatologie und Immunologie am Klinikum Bad Bramstedt und Sektion für Rheumatologie und Entzündliche Systemerkrankungen in der III. Medizin des Universitätsklinikum Eppendorf (UKE), Hamburg, Deutschland
| | - A Voormann
- Deutschen Gesellschaft für Rheumatologie e. V., Wilhelmine-Gemberg-Weg 6, 10179, Berlin, Deutschland.
| | - U Wagner
- Deutschen Gesellschaft für Rheumatologie e. V., Wilhelmine-Gemberg-Weg 6, 10179, Berlin, Deutschland
- Bereich Rheumatologie an der Klinik für Endokrinologie, Nephrologie und Rheumatologie, Universitätsklinikum Leipzig, Leipzig, Deutschland
| | - A Krause
- Deutschen Gesellschaft für Rheumatologie e. V., Wilhelmine-Gemberg-Weg 6, 10179, Berlin, Deutschland
- Abteilung Rheumatologie, Klinische Immunologie und Osteologie, Immanuel Krankenhaus Berlin, Berlin, Deutschland
| |
Collapse
|
3
|
Paz L, Beck Júnior A, Engelmann A, Mucha J, Frank M, Pereira R, Krause A, Côrte FDL. Effects of breed, age and gender on equine platelet rich plasma and correlation of platelet count with its physical aspect. ARQ BRAS MED VET ZOO 2022. [DOI: 10.1590/1678-4162-12517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
ABSTRACT Platelet rich plasma samples from 50 healthy horses of five different breeds (Thoroughbreds - TB, Brazilian Criollo Horses - BCH, Brazilian Sport Horses - BSH, Miniature Horses - MH and Crossbred Horses - CB), were investigated as to breed, age, and gender effect for platelet concentration. Moreover, a score for physical analysis was established to correlate PRP physical aspect with platelet count. Platelet count was performed by an automatic hematology analyzer and by manual count. PRP physical analysis was based on color, aspect, and capacity to separate blood components. MH showed significant higher platelet concentration than BSH (p<0.05), while the other breed comparisons showed no significant difference. There was no significant difference for gender but there was a weak correlation of age with PRP platelet concentrations (rs = -0.24). Most of the PRP presented yellow color, the separation of blood components showed no correlation, but the aspect showed a moderate correlation (rs = 0.30) with platelet count. Results suggest that PRP platelet concentration can be influenced by intrinsic factors such as breed. Additionally, the analysis of PRP aspect can help to evaluate the quality of the product when there is no access to platelet counts.
Collapse
Affiliation(s)
- L.B. Paz
- Universidade Federal de Santa Maria, Brazil
| | | | | | | | - M.I. Frank
- Universidade Federal de Santa Maria, Brazil
| | | | - A. Krause
- Universidade Federal de Santa Maria, Brazil
| | | |
Collapse
|
4
|
Benesova K, Hansen O, Sander O, Feuchtenberger M, Nigg A, Voigt A, Seipelt E, Schneider M, Lorenz HM, Krause A. [Further development of regional early care-Many roads lead to Rome : Developmental stages of four established rheumatological early care concepts in different regions of Germany]. Z Rheumatol 2022; 81:445-462. [PMID: 35670879 PMCID: PMC9171475 DOI: 10.1007/s00393-022-01220-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/03/2022] [Indexed: 11/25/2022]
Abstract
In order to shorten the prognostically relevant waiting time until diagnosis and initiation of appropriate treatment in inflammatory rheumatic diseases, rheumatological centers in many regions across Germany have established and continuously developed specific early care concepts. Evaluated models from Altötting·Burghausen, Berlin Buch, Düsseldorf and Heidelberg and their developmental stages as a response to internal and external challenges are presented in this overview. The transparent publication of the developmental steps and the exchange of experiences aim at promoting new early care concepts in other regions and continuing the joint dialogue for improvement of the early detection and quality of care of inflammatory rheumatic diseases in Germany.
Collapse
Affiliation(s)
- K Benesova
- Innere Medizin V, Sektion Rheumatologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland.
| | - O Hansen
- Innere Medizin V, Sektion Rheumatologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland
| | - O Sander
- Poliklinik und Funktionsbereich für Rheumatologie & Hiller Forschungszentrum Rheumatologie, UKD Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | - M Feuchtenberger
- MVZ MED|BAYERN OST Altötting·Burghausen, Burghausen, Deutschland
| | - A Nigg
- MVZ MED|BAYERN OST Altötting·Burghausen, Burghausen, Deutschland
| | - A Voigt
- Abteilung für Rheumatologie, Osteologie und Klinische Immunologie, Immanuel Krankenhaus Berlin, Berlin, Deutschland
| | - E Seipelt
- Abteilung für Rheumatologie, Osteologie und Klinische Immunologie, Immanuel Krankenhaus Berlin, Berlin, Deutschland
| | - M Schneider
- Poliklinik und Funktionsbereich für Rheumatologie & Hiller Forschungszentrum Rheumatologie, UKD Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | - H-M Lorenz
- Innere Medizin V, Sektion Rheumatologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland
- ACURA Rheumazentrum Baden-Baden, Baden-Baden, Deutschland
| | - A Krause
- Abteilung für Rheumatologie, Osteologie und Klinische Immunologie, Immanuel Krankenhaus Berlin, Berlin, Deutschland
| |
Collapse
|
5
|
Hasseli R, Hoyer BF, Lorenz HM, Pfeil A, Regierer A, Richter J, Schmeiser T, Strangfeld A, Voll R, Schulze-Koops H, Krause A, Specker C, Müller-Ladner U. POS1246 COVID-19 IN RITUXIMAB TREATED PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundAt the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) pandemic, the influence of anti-inflammatory therapy on the course of SARS-CoV-2 infection in patients with inflammatory rheumatic diseases (IRD) was unknown. In the meantime, several data indicate an association of severe courses of COVID-19 with the use of rituximab (RTX).ObjectivesTo gather further knowledge about SARS-CoV-2 infections in RTX-treated IRD patients, data from the German COVID-19-IRD-registry were analysed.MethodsHospitalisation was used as a surrogate of COVID-19 severity. Baseline characteristics, disease features, medication and outcome of COVID-19 were compared in RTX-treated inpatients and outpatients.ResultsIn total, 3592 cases were reported in the registry, which included 130 RTX patients (3.6%) for our analysis. RTX-treated inpatients were older than RTX-treated outpatients (median age 63 y vs 56 y, p=0.007). Patients with granulomatosis with polyangiitis treated with RTX (n=32) showed a significant higher COVID-19 related hospitalisation rate (33% vs 11%, p=0.005), which was not the case for patients with rheumatoid arthritis (49% vs 50%). Cardiovascular comorbidities were reported more frequently in hospitalised RTX-treated patients (20% vs. 6%, p=0.032). More than 50% of the RTX-treated inpatients developed COVID-19 related complications, e.g. acute respiratory distress syndrome. The median time period between the last RTX treatment and SARS-CoV-2 infection was shorter in inpatients than in non-hospitalised patients (3 (range 0-17) vs. 4 months (range -29), p=0.039). The COVID-19 related mortality rate was 14% (n=19) in RTX-treated IRD patients. In RTX-treated inpatients and outpatients, there were no relevant differences with respect to the use of concomitant glucocorticoids or other disease modifying anti-rheumatic drugs, disease activity, median last RTX dose or median number of immunomodulatory drugs prior to RTX treatment.ConclusionIn addition to general risk factors, such as age and comorbidities, it is already known that IRD patients treated with RTX show a higher rate of severe COVID-19. In our registry, RTX-treated patients with granulomatosis with polyangiitis appear to be at even higher risk to develop severe COVID-19 compared to other IRD. Moreover, the shorter the time since the last RTX treatment, the higher seems to be the risk of developing severe COVID-19. This might be explained by a more profound B-cell depletion in the first weeks after RTX treatment warranting further studies.Disclosure of InterestsNone declared
Collapse
|
6
|
Ramien R, Rudi T, Schneider M, Balzer S, Krause A, Schaefer M, Meissner Y, Strangfeld A. OP0306 IMPACT OF INFLAMMATION ON INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS - AN ANALYSIS OF THE GERMAN BIOLOGICS REGISTER RABBIT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundTen percent of patients with prevalent rheumatoid arthritis (RA) develop an interstitial lung disease (ILD), which is associated with higher mortality (1). A previous study identified high/moderate disease activity, but not CRP, as a risk factor for RA-ILD (2).ObjectivesTo analyse whether systemic inflammation (CRP and ESR) and/or disease activity measured with a composite score (DAS28-ESR) are associated with the occurrence of ILD in patients with RA.MethodsData from RA patients observed in the biologics register RABBIT until 10/2020 were included. Patients with incident ILD were selected as cases and matched 1:5 to controls using a modified risk-set sampling (controls had no ILD during the entire observation time). Matching criteria were age, sex, RA duration, date of enrolment and observation time. Odds ratios (OR) and 95% confidence intervals (CI) were computed by conditional logistic regression and adjusted for factors identified by a directed acyclic graph (DAG), namely smoking, rheumatoid factor (RF), chronic obstructive pulmonary disease, number of biologics until index date (date of ILD-diagnosis in cases, date after the respective observation time in controls) and mean glucocorticoid dosage (12 months prior index date). For the regression, CRP and ESR were log-transformed due to their skewed distribution, and missing values were addressed by multiple imputations (n=10).ResultsOut of 19,148 RA patients enrolled since 2001, 133 patients with incident ILD were identified. Half of the ILDs were diagnosed by computed tomography (n=67), 8% by x-ray (n=10) and in 42% the method was unknown (n=56).At baseline, cases and controls had a mean age of 61 years, 68% were female, and mean RA disease duration was 9 years. Differences were observed in smoking status (59% ever smokers in cases vs. 48% in controls), RF positivity (84% vs. 72%) and the sum of comorbidities (means 3.1 vs. 2.3).During the 12 months prior to the index date, mean values of CRP and especially of ESR were significantly higher in cases compared to controls. This difference was not observed for DAS28 (Figure 1, upper figures). Furthermore, more cases than controls were in a high inflammatory status, but not in at least moderate disease activity (Figure 1, lower figures). The adjusted regression analyses confirmed these results: CRP and ESR were significantly associated with incident ILD both at the time of diagnosis and in the 12 previous months, and results were even more pronounced with elevated CRP and ESR, which was not the case for DAS28 (Table 1).Table 1.Results of the conditional logistic regression for the risk of ILD.Crude OR (95% CI)Adjusted OR (95% CI)At index dateLog CRP1.55 (1.25 – 1.92)1.55 (1.24 – 1.94)CRP≥5 vs. CRP<52.43 (1.55 – 3.81)2.41 (1.49 – 3.88)Log ESR1.56 (1.22 – 2.00)1.56 (1.21 – 2.01)ESR >21 vs. ESR ≤212.12 (1.40 – 3.19)2.12 (1.37 – 3.29)DAS281.17 (1.01 – 1.35)1.16 (0.99 – 1.35)DAS28 >3.2 vs. DAS28 ≤3.21.31 (0.86 – 1.99)1.32 (0.85 – 2.06)Within 12 months prior to index dateLog CRP1.41 (1.14 – 1.75)1.38 (1.09 – 1.74)CRP≥5 vs. CRP<52.60 (1.59 – 4.27)2.60 (1.54 – 4.41)Log ESR1.65 (1.26 – 2.16)1.60 (1.21 – 2.12)ESR >21 vs. ESR ≤212.43 (1.53 – 3.86)2.35 (1.45 – 3.81)DAS281.16 (0.99 – 1.36)1.13 (0.95 – 1.34)DAS28 >3.2 vs. DAS28 ≤3.21.37 (0.82 – 2.30)1.37 (0.79 – 2.35)Figure 1. Upper Figures. Unimputed and untransformed CRP, ESR and DAS28 12 months prior to the index date as means with 95% CI, computed by mixed models with matching strata as random effects. The left y-axis refers to CRP and ESR, the right to DAS28. Lower Figures. Percentages of patients with CRP≥5, ESR>21 and DAS28>3.2 12 months prior to the index date.ConclusionIn contrast to other data, our analyses found that markers of systemic inflammation, but not the DAS28 composite score, are associated with the occurrence of incident ILD in patients with RA and can be predictors for the development of RA-ILD. Therefore, in a treat-to-target approach, rheumatologists should pay particular attention to controlling systemic inflammation.References[1]PMID: 20851924[2]PMID: 30951251AcknowledgementsRABBIT is supported by a joint, unconditional grant from AbbVie, Amgen, BMS, Fresenius-Kabi, Galapagos, Hexal, Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis, Viatris and UCB.Disclosure of InterestsRonja Ramien: None declared, Tatjana Rudi: None declared, Matthias Schneider Speakers bureau: Astra-Zeneca; Biogen; BMS; Celgene; Chugai; GSK; Janssen-Cilag; Lilly; Pfizer; UCB, Paid instructor for: Lilly, Consultant of: Abbvie; Astra-Zeneca; Boehringer-Ingelheim; GSK; Lilly; Novartis; Pfizer; Protagen; Roche; Sanofi-Aventis; UCB, Grant/research support from: Abbvie; Astra-Zeneca; GSK; UCB, Sabine Balzer: None declared, Andreas Krause Speakers bureau: AbbVie, BMS, Boehringer Ingelheim, Celgene, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, UCB, Consultant of: AbbVie, BMS, Boehringer Ingelheim, Galapagos, Janssen, Lilly, MSD, Mylan, Novartis, Pfizer, Roche, Grant/research support from: AbbVie, UCB, Martin Schaefer: None declared, Yvette Meissner Speakers bureau: Pfizer, Anja Strangfeld Speakers bureau: AbbVie, Amgen, BMS, Celltrion, Janssen, Lilly, Pfizer, Roche, Sanofi, UCB.
Collapse
|
7
|
Beckmann D, Krause A, Hansen U, Kiener H, Kremerskothen J, Pavenstädt H, Pap T, Korb-Pap A. POS0446 Arp2/3 AS A Lasp1 INTERACTION PARTNER REGULATES CELL-TO-CELL CONTACT FORMATION OF FIBROBLAST-LIKE SYNOVIOCYTES IN RA. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundIn rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) undergo a stable transformation resulting in an aggressive phenotype mediating cartilage damage by increased levels of adhesion molecules. In this context, Lasp1 and the Arp2/3 complex are of interest because they modulate actin organization and focal adhesion turnover.ObjectivesIn this study, the effects of Arp2/3 on cadherin-11 mediated cell-to-cell contact formation have been investigated using the arthritic hTNFtg mouse model.MethodsExpression levels of Lasp1 and Arp2/3 protein complex were investigated in synovial tissue of wild type (wt) and hTNFtg hind paws by immunohistochemistry. Primary FLS were analysed, respectively and co-immunoprecipitation experiments were performed. In addition, lasp1-/- mice were interbred with hTNFtg animals and offspring were evaluated for disease progression and joint destruction. To further study the role of Arp2/3 in the function of the cadherin-11 adhesion complex, the effects of an Arp2/3 inhibitor (CK666) on cell-to-cell contact formation in FLS derived from hTNFtg and lasp1-/-hTNFtg mice were investigated by stainings. To assess signaling pathway activation, cells were stimulated with the growth factor PDGF.ResultsUpregulated Lasp1 levels were found in synovial tissue and FLS of hTNFtg compared to wt mice. Assays showed that Arp2/3 is part of the adherens junction (AJ) machinery in FLS although Arp2/3 expression levels were not changed between the genotypes. In vivo evaluation of lasp1-/-hTNFtg mice revealed a milder arthritis score, less cartilage degradation and reduced FLS attachment to articular cartilage compared to hTNFtg mice. In vitro, the loss of Lasp1 led to clear alterations in AJ arrangement indicated by altered β-catenin pattern. As expected, β-catenin expression was mainly located at adhesion sites between adjacent cells. In hTNFtg FLS, these structures were characterized by a zipper-like pattern. In contrast, these structures were disrupted in lasp1-/-hTNFtg FLS. Interestingly, CK666 induced zipper-like structures in hTNFtg FLS comparable to the pattern found in lasp1-/-hTNFtg cells. Furthermore, lasp1-/-hTNFtg FLS showed decreased Src phosphorylation following PDGF stimulation in comparison to hTNFtg FLS.ConclusionLasp1 represents an interesting target involved in RA-caused joint destruction, because its loss results in significantly reduced cartilage destruction and altered FLS contacts mediated by Arp2/3.Disclosure of InterestsNone declared.
Collapse
|
8
|
Schönau V, Corte G, Ott S, Tascilar K, Hartmann F, Manger B, Hellmich B, Pfeil A, Oelzner P, Schmidt WA, Krause A, Schmalzing M, Fröhlich M, Gernert M, Venhoff N, Henes J, Rech J, Schett G. POS0809 CHARACTERIZATION OF RELAPSES IN PATIENTS WITH GIANT CELL ARTERITIS (GCA) PATIENTS- DATA FROM THE REAL-LIFE TREATMENT AND SAFETY (REATS)-GCA COHORT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundGiant cell arteritis (GCA) has the tendency to relapse once treatment is tapered or stopped. Such relapses represent a potential threat to GCA patients as they can lead to severe symptoms and organ damage.ObjectivesTo assess the frequency and type of relapses in patients with GCAMethodsThe Real-Life Treatment and Safety (REATS)-GCA cohort has been established by extracting the data on clinical presentation, inflammatory markers, imaging, comorbidities, treatments and serious adverse events of GCA patients from 6 specialized centres in Germany. We undertook descriptive and survival analyses (Kaplan-Meier), and compared baseline characteristics of participants with vs. without relapse. Ethical approval for the cohort was obtained.ResultsWe included 395 patients with a mean age of 71 years, including 264 (66.8 %) females and 129 (32.7%) males. Diagnosis of GCA was supported by temporal artery ultrasound in 37%, 18F-FDG-PET/CT in 29%, temporal artery biopsy in 14% of patients and by MRI or clinically in the remaining patients. 31% of patients presented with an isolated cranial manifestation and 18% with isolated extracranial manifestations. Most common presenting symptoms were headache (57%), fatigue (55%), weight loss (42%) and polymyalgia (38%) (Table 1). The most common comorbidities at the time of study inclusion were arterial hypertension (68%), followed by osteoporosis (26%). Within a median total follow-up duration of 22.2 (11.7-40.6) months, 97 of the 395 patients relapsed including 15 patients who relapsed more than once. The median (IQR) time to first relapse was 12.5 (7.1-21.8) months. Median relapse-free survival was 7.8 years with a relapse risk of 12% (CI, 9 to 15%) at 1 year and 38% (CI, 30 to 45%) at 5 years (Figure 1). Most common symptoms at relapse were headache (35%), polymyalgia (23%), fatigue (19%) and night sweats (12%) (Table 1). Three patients relapsed with sudden loss of vision. Among the 114 relapses observed, 94 (83%) occurred under prednisolone treatment with a median dose of 7.0 mg/day (IQR 4.0-12.5). 26 (23%) occurred under methotrexate and 14 (12%) under tocilizumab treatment. Comparing the baseline characteristics that were documented in this study, we did not find a statistically significant difference in relapsing versus non-relapsing GCA patients.Table 1.Symptom at disease onsetN=395 (%)Symptom at relapseN=97 (%)Headache216 (54.7)Headache35 (30.7)Fatigue208 (52.7)Polymyalgia (PMR)23 (20.2)Weight loss159 (40.3)Fatigue19 (16.7)Polymyalgia (PMR)144 (36.5)Vision impairment13 (11.4)Night sweats140 (35.4)Night sweats12 (10.5)Headache in the temple area125 (31.6)Headache in the temple area12 (10.5)Jaw pain121 (30.6)Jaw pain11 (9.6)Vision impairment118 (29.9)Morning stiffness7 (6.1)Morning stiffness89 (22.5)Weight loss7 (6.1)Fever80 (20.3)Claudication upper limb6 (5.3)Swelling temporal arteries77 (19.5)Arthralgia6 (5.3)Vision loss57 (14.4)Claudication lower limb5 (4.4)Scalp tenderness38 (9.6)Vision loss3 (2.6)Claudication upper limb38 (9.6)Arthritis3 (2.6)Claudication lower limb34 (8.6)Scalp tenderness2 (1.8)Arthralgia28 (7.1)Fever2 (1.8)Arthritis3 (0.8)Swelling temporal arteries2 (1.8)Figure 1.ConclusionAbout one fourth of GCA patients relapsed and the overwhelming majority of relapses occurred before patients were able to stop glucocorticoids. The leading symptoms at relapse are headache and fatigue, while loss of vision is rare (0.76%). Baseline characteristics seem to be poorly informative about the risk of relapse, therefore regular monitoring of GCA patients is necessary.AcknowledgementsThis research was financially supported by Roche Pharma Ag and Chugai Pharma Europe Ltd.Disclosure of InterestsVerena Schönau Speakers bureau: Novartis, Janssen, Grant/research support from: Roche, Chugai, Giulia Corte: None declared, Sebastian Ott: None declared, Koray Tascilar: None declared, Fabian Hartmann: None declared, Bernhard Manger: None declared, Bernhard Hellmich: None declared, Alexander Pfeil: None declared, Peter Oelzner: None declared, Wolfgang A. Schmidt: None declared, Andreas Krause: None declared, Marc Schmalzing: None declared, Matthias Fröhlich: None declared, Michael Gernert: None declared, Nils Venhoff: None declared, Jörg Henes: None declared, Jürgen Rech Speakers bureau: Abbvie, Biogen, BMS, Chugai, GSK, Lilly, MSD; Novartis, Roche, Sanofi, Sobi, UCB,, Consultant of: Biogen, BMS, Chugai, GSK, Lilly, MSD, Novartis, Roche, Sanofi, Sobi, UCB, Grant/research support from: Sobi, Novartis, Georg Schett: None declared
Collapse
|
9
|
Hasseli R, Hoyer BF, Lorenz HM, Pfeil A, Regierer A, Richter J, Schmeiser T, Strangfeld A, Krause A, Voll R, Schulze-Koops H, Müller-Ladner U, Specker C. OP0179 CHARACTERISTICS AND OUTCOMES OF SARS-CoV-2 BREAKTHROUGH INFECTIONS AMONG DOUBLE AND TRIPLE VACCINATED PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundSARS-CoV-2 vaccines offer the most effective way to reduce the risk of severe COVID-19. Recent data indicate sufficient immune response after vaccination in most patients with inflammatory rheumatic diseases (IRD) on immunomodulatory treatments.ObjectivesTo investigate the clinical profile of SARS-CoV-2 breakthrough infections among double and triple vaccinated patients with IRD.MethodsData from the German COVID-19-IRD registry, collected by treating rheumatologists between February 2021 and January 2022 were analysed. Patients double or triple vaccinated against COVID-19 ≥14 days prior to proven SARS-CoV-2 infection were identified, and type of IRD, vaccine, immunomodulation, comorbidities and outcome of the infection were compared with 737 unvaccinated IRD-patients with COVID-19.ResultsIn total, 271 cases of breakthrough infections were reported, 250 patients (91%) had received two doses of vaccines, 21 (9%) patients three. More than 70% of the patients received Pfizer/Biontech vaccine for the first, second and third vaccination. The median time from second/third vaccine dose to infection was 148 days (range 14-302) days. Most of the patients were diagnosed with inflammatory joint diseases (Table 1). Most of the patients were treated with methotrexate (Table 1). The use of Januskinase inhibitors(i) was more frequently reported in double vaccinated patients (10.4% vs 4.8%), whereas tumor necrosis (TNF)i were reported more often in triple vaccinated patients (33.3% vs. 22.8). Hospitalisation rate was higher in unvaccinated IRD-patients than in vaccinated ones, while fatality rate was similar in unvaccinated and double vaccinated patients. Although the rate of comorbidities and median age were higher in triple-vaccinated patients, infected patients showed a lower rate of hospitalisation, neither COVID-19 related complications, nor the need of oxygen treatment or death.Table 1.Profile of vaccinated IRD patientsunvaccinated2ndvaccination3rdvaccinationNumber (737)%Number (250)%Number (21)%Age56 (18-93)57 (22-90)63 (35-88)Female47864.915863.21361.9BMI26.8 (17-53)26.7 (17-55)25.4 (18-41)Inflammatory rheumatic disease (multiple selections possible)Inflammatory joint diseases56175.918674.41676.2Connective tissue diseases10112.8301229.6Vasculitis719.6228.8314.3Other IRD638.52911.614.8Immunomodulation (multiple selections possible)Glucocorticoid21228.86726.8523.8Methotrexate27036.69036838.1Azathioprine192.672.8//Cyclosporine30.410.4//Leflunomide506.872.8//Hydroxychloroquine7910.7239.214.8Sulfasalazine202.793.6//JAKi547.32610.414.8TNFi15821.45722.8733.3Abatacept91.231.2//Rituximab212.8114.414.8Other biologics597.93212.829.6Mycophenolate15241.6//Immunoglobulines20.310.4//Apremilast40.5////Cyclophosphamide10.110.4//No immunomodulation7410228.814.8No/low disease activity62584.822389.21885.7Moderate/high disease activity10213.82710.8314.3ComorbiditiesCardiovascular diseases32944.6130521361.9Diabetes mellitus7610.32510//Osteoporosis435.8218.429.5Chronic renal failure405.4166.4419Cancer/history of cancer152.0104314.3COPD253.4104//ILD162.272.8//Bronchial asthma344.6166.4//Pregnancy70.910.414.8No comorbidity25434.59738.8523.8Complications due to COVID-19Hospitalisation13518.32911.629.5Oxygen treatment11415.5249.6//Invasive ventilation253.493.6//Death162.272.8//ConclusionIn this cohort of triple-vaccinated IRD patients no fatal courses and no COVID-19 related complications were reported, although median age and rate of comorbidities were higher compared to double-vaccinated and unvaccinated patients. These results support the general recommendations to reduce the risk of severe COVID-19 disease by administering three doses of vaccine, especially in patients with older age, presence of comorbidities, and on immunomodulatory treatment.Disclosure of InterestsNone declared
Collapse
|
10
|
Giertzsch T, Kölbel T, Müller G, Kozlik-Feldmann R, Schneider P, Zengin-Sahm E, Sinning C, Lang N, Redlefsen T, Peldschus K, Weinrich J, Krause A, Rickers C. Unentdeckte Aortenisthmusstenosen (CoAs) als Ursache für ungeklärte arterielle Hypertonien bei Jugendlichen und Erwachsenen. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1743006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- T. Giertzsch
- University Heart Center Hamburg GmbH, Hamburg, Deutschland
| | - T. Kölbel
- Vascular Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland
| | - G. Müller
- Pediatric Cardiology, University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland
| | | | - P. Schneider
- University Heart Center Hamburg GmbH, Hamburg, Deutschland
| | - E. Zengin-Sahm
- University Heart Center Hamburg GmbH, Hamburg, Deutschland, Hamburg, Deutschland
| | - C. Sinning
- Department of Cardiovascular Surgery, University Heart Center Hamburg GmbH, Hamburg, Deutschland
| | - N. Lang
- Department of Pediatr Cardiology, Children's Heart Clinic, Univ Med Center Eppendorf, Hamburg, Deutschland
| | - T. Redlefsen
- University Heart Center Hamburg GmbH, Hamburg, Deutschland
| | - K. Peldschus
- University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland
| | - J. Weinrich
- University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland
| | - A. Krause
- University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland
| | - C. Rickers
- University Heart Center Hamburg GmbH, Hamburg, Deutschland
| |
Collapse
|
11
|
Meyer F, Engel A, Krause A, Wagner T, Poole L, Dubrovska A, Peitzsch C, Petersen C, Rothkamm K, Borgmann K. OC-0401 Avoidance of DNA Replication Stress Leads to Decreased Cytosolic DNA in Breast Cancer Stem Cells. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06888-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
12
|
Frommherz L, Krause A, Kopp J, Hotz A, Hübner S, Reimer-Taschenbrecker A, Casetti F, Zirn B, Fischer J, Has C. High rate of self-improving phenotypes in children with non-syndromic congenital ichthyosis: case series from south-western Germany. J Eur Acad Dermatol Venereol 2021; 35:2293-2299. [PMID: 34273205 DOI: 10.1111/jdv.17524] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Accepted: 07/02/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND Non-syndromic congenital ichthyosis describes a heterogeneous group of hereditary skin disorders associated with erythroderma and scaling at birth. Although both severe and mild courses are known, the prediction of the natural history in clinical practice may be challenging. OBJECTIVES To determine clinical course and genotype-phenotype correlations in children affected by non-syndromic congenital ichthyosis in a case series from south-western Germany. METHODS We performed a retrospective observational study of 32 children affected by non-syndromic congenital ichthyoses seen in our genodermatosis clinic between 2011 and 2020. Follow-ups included assessment of weight and severity of skin involvement utilizing a modified Ichthyosis Area Severity Index (mIASI). mIASI was calculated as a sum comprising the previously published IASI score and an additional novel score to evaluate palmoplantar involvement. Linear regression was assessed using Pearson correlation, and statistical analysis was performed using the Wilcoxon-Mann-Whitney test. RESULTS This study included 23 patients with autosomal recessive congenital ichthyosis, seven with keratinopathic ichthyosis and two with harlequin ichthyosis. Cutaneous manifestations improved in more than 70% of the children during the follow-up. Especially in patients with mutations in ALOXE3 and ALOX12B, mIASI scores dropped significantly. The most common phenotype observed in this study was designated 'mild fine scaling ichthyosis'. Severe palmoplantar involvement occurred in patients with KRT1 and ABCA12 mutations; most patients demonstrated hyperlinearity as a sign of dryness and scaling. Weight was mainly in the normal range and negatively correlated with the severity of skin involvement. CONCLUSIONS Congenital ichthyosis that self-improves and evolves with mild fine scaling ichthyosis was the most common phenotype observed in our patients. This type might be underdiagnosed if the genetic diagnosis is not performed in the first year of life. mIASI is an easy and fast instrument for scoring disease severity and adding additional points for palmoplantar involvement might be valuable.
Collapse
Affiliation(s)
- L Frommherz
- Faculty of Medicine, Department of Dermatology, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.,Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany
| | - A Krause
- Faculty of Medicine, Department of Dermatology, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany
| | - J Kopp
- Institute of Human Genetics, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany
| | - A Hotz
- Institute of Human Genetics, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany
| | - S Hübner
- Faculty of Medicine, Department of Dermatology, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany
| | - A Reimer-Taschenbrecker
- Faculty of Medicine, Department of Dermatology, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany
| | - F Casetti
- Faculty of Medicine, Department of Dermatology, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany
| | - B Zirn
- Genetikum® Stuttgart, Genetic Counselling and Diagnostics, Stuttgart, Germany
| | - J Fischer
- Institute of Human Genetics, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany
| | - C Has
- Faculty of Medicine, Department of Dermatology, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany
| |
Collapse
|
13
|
Weiß K, Schmidt WA, Krause A, Schäfer VS. A study on echocardiographic findings in hospitalized patients with connective tissue diseases. Scand J Rheumatol 2021; 51:142-151. [PMID: 34229550 DOI: 10.1080/03009742.2021.1911053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
OBJECTIVE To determine the prevalence of echocardiographic findings and their change over time in patients with connective tissue diseases (CTDs) and to analyse which findings were associated with escalation of immunosuppressive therapy. METHOD We conducted a retrospective cohort study of consecutive hospitalized patients from a tertiary rheumatology referral centre who received transthoracic echocardiography between 1 January 2006 and 31 December 2015. We tested for associations between echocardiographic findings and treatment escalation via Fisher's exact test; p < 0.05 was considered significant. Escalation of therapy was defined by dosage of glucocorticoids and type of disease-modifying anti-rheumatic drug. The clinical relevance of echocardiographic findings concerning change in immunosuppressive therapy was recorded. RESULTS In total, 1004 patients were included (865 females), with a total of 1660 echocardiographic examinations. The most frequent findings were mitral, tricuspid, and aortic valve regurgitation (found in 36.7%, 25.4%, and 17.7% of all patients), aortic valve sclerosis (20.1%), left ventricular dysfunction (21.5%), and left atrial dilatation (19.2%). Only pericardial effusions were more frequent in cases with treatment escalation (10.9% of cases with escalated therapy vs 6.9% of cases without, p = 0.007). In 314 patients who received follow-up examinations, echocardiographic findings were found to change between examinations. Only 73 of all 1660 examinations were discussed in depth considering the treatment strategy in the hospital discharge letter. CONCLUSION Patients with CTDs exhibited a wide, dynamically changing spectrum of echocardiographic abnormalities. Most findings neither reflected disease activity nor appeared to influence the therapeutic regimen.
Collapse
Affiliation(s)
- K Weiß
- Department of Internal Medicine, Asklepios Nordseeklinik Westerland GmbH, Sylt, Germany
| | - W A Schmidt
- Department of Rheumatology, Immanuel Krankenhaus Berlin Buch, Berlin, Germany
| | - A Krause
- Department of Rheumatology, Immanuel Krankenhaus Berlin Buch, Berlin, Germany
| | - V S Schäfer
- Clinic of Internal Medicine III, Department of Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany
| |
Collapse
|
14
|
Hasseli R, Hoyer BF, Krause A, Lorenz HM, Pfeil A, Regierer A, Richter J, Schmeiser T, Strangfeld A, Schulze-Koops H, Voll R, Specker C, Müller-Ladner U. OP0283 DOES TNF-INHIBITION DECREASE THE RISK OF SEVERE COVID-19 IN RMD-PATIENTS? Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.4027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Patients with rheumatic and musculoskeletal diseases (RMD) might have an increased risk for infection due to their immunomodulatory treatment, secondary to their disease and comorbidities. Recent studies suggest a decreased risk of severe COVID-19 in RMD-patients treated with biologics.Objectives:The aim of this study was to assess courses of RMD patients treated with TNF-inhibitors (TNF-I) included in the German COVID-19 registry.Methods:In the German physician-reported COVID-19-RMD registry, patients with an RMD and confirmed SARS-CoV-2-infection were documented (data entered between March 30, 2020 and January 30, 2021). We analysed TNF-I treated patients, their course and outcome of the infection. Data were compared to RMD-patients treated with other immunomodulatory drugs (OID) than TNF-I.Results:A total of 269 patients were treated with a TNF-I (57% female) compared to 874 patients who were treated with OID (68% female). Median age was 52 years (range: 19-87) in the TNF-I-group versus 58 years (range: 18-91) in the OID-group. Rheumatoid arthritis was the most common diagnosis (38% in TNF-I-group vs. 52% in the OID-group), followed by ankylosing spondylitis (32% vs. 6%), psoriatic arthritis (22% vs. 11%) and other RMD (9% vs. 31%). Adalimumab (35%) and etanercept (35%) were the most frequently used TNF-I (tab. 1). Glucocorticoids (GC) were used in 22% of TNF-I-treated patients and in 42% of the OID-group.Under TNF-I, stable disease was reported prior to the SARS-CoV-2-infection in 53% of the patients (OID-group: 47%), followed by low disease activity in 35% (OID: 34%), moderate disease activity in 6% (OID: 12%) and high disease activity in 4% (OID: 3%). Most frequent comorbidities were arterial hypertension (29% under TNF-I vs. 35% under OID), diabetes (8% vs. 11%) and cardiovascular diseases (7% vs. 12%).The most common reported COVID-19 symptoms were dry cough (57% vs. 55%), fever (53% vs. 61%) and fatigue (50% vs. 49%). Hospitalization due to SARS-CoV infection was required in only 12% of the TNF-I-treated cases vs. in 29% in the OID-group. Oxygen treatment was necessary in 5% of the patients under TNF-I compared to 22% under OID and invasive ventilation in 2% in the TNF-I-group compared to 6% under OID. Most notably, no fatal courses of COVID-19 were reported among the 269 RMD-patients treated with TNF-I versus 49 deaths in the 874 cases (5.6%) treated with OID. Focussing on the hospitalizated TNF-I patients, the rate of concomitant GC use (p<0.001) and higher disease activity (p=0.005) was significant higher (tab.1).Conclusion:High or moderate RMD-disease activity is an important factor associated with severity of COVID-19 including mortality. In this large cohort RMD patients treated with TNF-I show a low hospitalisation rate and no fatal course. This is reassuring for patients and treating rheumatologists to use TNF-I to control RMD disease activity. The use of glucocorticoids and high disease activity seem to counteract possible protective effects of TNF-I.Table 1.TNF inhibition (269)Other immunomodulation (874)Total patientsRate (%)Total patientsRate (%)Disease activitystable1415340847low933529934Moderate15610812High104293Comorbiditiescardiovascular diseases18710412arterial hypertension772930335bronchial asthma124657COPD/interstitial lung disease1148610chronic renal failure93779Osteoporosis135678Diabetes2289211COVID-19 related symptomsFever1425347855dry cough1525753061Expectoration3112839muscular pain973628032Fatigue1355042449Headache1013823727shortness of breath491824528no symptoms239566COVID-19 outcomeOutpatients2378861971Inpatients321225529need of oxygen treatment18718922invasive ventilation52496fatal course00496TNF inhibitorsAdalimumab9535Infliximab239Certolizumab3312Golimumab249Etanercept9435GC and disease activity in TNF-I treated patientsTNF-I inpatients treated with GC18/3256p< 0.001TNF-I outpatients treated with GC42/23718TNF-I inpatients with high disease activity4/3213TNF-I outpatients with high disease activity6/2376p= 0.005Acknowledgements:The authors would like to thank all physicians and personnel involved in the documentation of the cases in our registry.Disclosure of Interests:None declared
Collapse
|
15
|
Hasseli R, Müller-Ladner U, Schmeiser T, Lorenz HM, Krause A, Schulze-Koops H, Pfeil A, Regierer A, Richter J, Strangfeld A, Voll R, Specker C, Hoyer BF. POS1261 DISEASE ACTIVITY AND PAIN LEVELS ARE NOT INFLUENCED BY THE CURRENT COVID19 PANDEMIC IN PATIENTS WITH RHEUMATIC DISEASES IN GERMANY – DATA FROM THE GERMAN COVID-19 PATIENT SURVEY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.4002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:The current pandemic constitutes an entirely new situation for patients as well as physicians. The insecurity of the early phase, shutdowns, increasing infection rate and appearing SARS-CoV2 mutations have created a situation that makes live difficult especially for chronic diseases i.e. patients with rheumatic and musculoskeletal diseases (RMD) and their treating physicians. The psychosocial burden that is created by this special situation is completely unknown and is estimated to be higher in patients than in the general population.Objectives:In order to measure the impact on our patients, the German COVID19-Rheuma patient survey was set up in April 2020, during Germany’s first shut down.Methods:The German COVID19-Rheuma patient survey is a patient reported longitudinal online survey where patients with RMD who registered between April and July 2020 are asked on a monthly base using an online survey on social, personal, medical factors, whether a COVID19 infection occurred, isolation measures were changed and scores regarding stress and anxiety are recorded. Between April and July 2020, 637 patients registered and completed a first survey. Up to January 2021, about 400 patients are still enrolled.Here we present an interim analysis of the first 6 months regarding patients that were enrolled in April and May during the first shut-down. This first analysis compares the situation in the first lockdown to July, a phase with very low infection numbers in Germany, and to November, the beginning of the second lockdown.Results:150 patients (87% female) were enrolled in April/early May 2020. Mean age was 48 years (range 11-89). The majority of patients suffered from rheumatoid arthritis (51%), followed by psoriatic arthritis (17%), other spondyloarthropathies (10%) and connective tissue diseases (10%).The majority of patients received antirheumatic therapies: 32% glucocorticoids (GC), 31% cDMARDs, 21% TNF inhibitors, 7% Jak inhibitors, and 9% other biologicals. Of the patients treated with GC, 25% were on GC monotherapy.In the first lockdown, 26% of patients were working remotely and 24% were self-isolating (doubles included). Additionally, 48% were using masks that were not mandatory at that time and 41% were using disinfection in a regular manner. The rates for remote work and self-isolation did not change significantly over time while the mask use increased to 98% with the official obligation to do so. The use of disinfectants increased to 88% in November.Regarding disease activity, no change in patient global assessment could be observed over time (4.3 ± 2.5 vs. 4.0 ±2.6 and 4.0 ± 2.5). Self-reported pain was also stable over time as were sleep disturbances. While 48.2% of patients who were receiving physiotherapy paused in April, only 10 and 14% did so in July and November, respectively. 11% of the patients paused their medication in the first lockdown, whereas only 2.75% did so in July and 3.4% in November. Contact with the treating rheumatologist was maintained over time in the majority of cases.Conclusion:While in the beginning of the pandemic the insecurity was considerable and the concern that the fear for infection would lead to inadequately treated patients with RMDs, we here show for the first time that on the one hand our patients were timely in taking adequate measures to keep themselves safe (e.g. self-isolating, mask use) and adapted to the clinical situation in not pausing their medication. Altogether, in this alert cohort, the pandemic did not lead to an increase of patient-reported disease activity in the first six months.Acknowledgements:Thanks goes to all patients who participated in the study.Disclosure of Interests:None declared
Collapse
|
16
|
Lakomek HJ, Rudwaleit M, Hentschel A, Broge B, Abrolat J, Bessler F, Hellmich B, Klemann A, Krause A, Klass M, Strunk J, Fiori W, Roeder N, Braun J. [Quality in acute inpatient rheumatology 2021 : Current aspects of the KOBRA quality label of the Association of Rheumatological Acute Care Clinics]. Z Rheumatol 2021; 80:758-770. [PMID: 33999267 PMCID: PMC8127451 DOI: 10.1007/s00393-021-01015-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/08/2021] [Indexed: 12/02/2022]
Abstract
Mit einer umfassenden gesundheitspolitischen Qualitätsoffensive ab 2021 sollen die Qualität und Transparenz in der Versorgung von Menschen mit Krankheiten in Krankenhäusern in Deutschland verbessert werden. Gesetzliche Vorgaben zu Mindestmengen und die Ausweitung von Qualitätsverträgen zwischen Kostenträgern und Krankenhäusern sowie die Verwendung von planungsrelevanten Qualitätsindikatoren für eine bedarfs- und qualitätsorientierte Weiterentwicklung der stationären Versorgung werden den Wettbewerb in der Versorgungsqualität zwischen den Krankenhäusern verstärken. Dem Thema „Entwicklung und Definition von Qualität in der Medizin“ hat sich auch der Verband der Rheumatologischen Akutkliniken e. V. (VRA) schon früh nach der Gründung im Jahr 1998 umfassend angenommen. Im Zentrum der akutstationären Qualitätssicherung stehen verbindlich festgelegte Strukturkriterien in Verknüpfung mit dem 2003 in der Rheumatologie gestarteten und bis heute kontinuierlich durchgeführten KOBRA-Projekt (Kontinuierliches Outcome Benchmarking in der Rheumatologischen Akutversorgung) mit der Messung von Prozess- und Ergebnisqualität. Auf der Basis dieses Rahmenkonzeptes (Erfüllung der Strukturkriterien und Durchführung des KOBRA-Projektes) können erfolgreich teilnehmende rheumatologische Einrichtungen für jeweils 2 Jahre das KOBRA-Label erwerben, welches von der Projektleitung – dem aQua-Institut – vergeben wird. Die herausragende Stellung des KOBRA-Projektes wird beispielhaft anhand von Datenauswertungen des Projektzyklus 2018 gezeigt mit Auswertungen zum Therapiestrategiewechsel bei aktiver rheumatoider Arthritis, Diagnosesicherung von Kollagenosen und Vaskulitiden während des stationären Aufenthaltes sowie zur partizipativen Entscheidungsfindung bei rheumatoider Arthritis. Auf den gesundheitspolitisch geforderten „Paradigmenwechsel – weg vom Bett, hin zu einer leistungs-, bedarfs- und qualitätsorientierten Planung“ – ist die akutstationäre Rheumatologie mit der Verankerung von Projekten zur Struktur‑, Prozess- und Ergebnisqualität sehr gut vorbereitet. Für die in der vom Gemeinsamen Bundesausschuss (G-BA) erstellten Richtlinie zu „Rheumatologischen Zentren“ geforderten Qualitätssicherung ist das KOBRA-Projekt ebenfalls eine sehr gute Voraussetzung.
Collapse
Affiliation(s)
- H-J Lakomek
- Universitätsklinik für Geriatrie, Johannes-Wesling-Klinikum Minden, Hans-Nolte-Str. 1, 32429, Minden, Deutschland.
| | - M Rudwaleit
- Universitätsklinik für Innere Medizin und Rheumatologie, Klinikum Bielefeld Rosenhöhe, Bielefeld, Deutschland
| | - A Hentschel
- aQua - Institut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen GmbH, Göttingen, Deutschland
| | - B Broge
- aQua - Institut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen GmbH, Göttingen, Deutschland
| | - J Abrolat
- Klinik an der Weißenburg, Uhlstädt-Kirchhasel, Deutschland
| | - F Bessler
- Geschäftsbereich Medizin, Ev. Stiftung Volmarstein, Wetter, Deutschland
| | - B Hellmich
- Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim, Kirchheim unter Teck, Deutschland
| | - A Klemann
- St.-Josef-Stift Sendenhorst, Sendenhorst, Deutschland
| | - A Krause
- Rheumatologie und Klinische Immunologie, Immanuel Krankenhaus Berlin, Berlin-Wannsee, Deutschland
| | - M Klass
- Rheumatologie und Physikalische Therapie, Helios Klinikum Duisburg, Duisburg, Deutschland
| | - J Strunk
- Abteilung Rheumatologie, Krankenhaus Porz am Rhein, Köln, Deutschland
| | - W Fiori
- Roeder & Partner, Ärzte Partnerschaftsgesellschaft, Senden, Deutschland
| | - N Roeder
- Roeder & Partner, Ärzte Partnerschaftsgesellschaft, Senden, Deutschland
| | - J Braun
- Rheumazentrum Ruhrgebiet, Herne, Deutschland
- Ruhr-Universität Bochum, Herne, Deutschland
| |
Collapse
|
17
|
Abstract
ABSTRACT We investigated the local and systemic effects of hyperbaric oxygen therapy in BALB/C mice, exposed to two different exposure times, under 2.4 atmosphere (ATM). Fifteen animals were divided into three groups (GI, GII and Control) and underwent a surgical excision of a skin fragment of approximately one square centimeter of the dorsal region. The wounds were treated and monitored for 21 days. In the control group, the wound was cleaned once a day with sterile 0.9% NaCl solution. GI and GII mice were submitted to daily hyperbaric oxygen therapy of 30 or 60minutes sessions, respectively. The wounds were photographed every three days and their surfaces were analyzed by an image analyzer. At 21 days, all animals were euthanatized for histopathological analysis of the skin, lungs and liver in order to identify eventual alterations in wound healing or in the analyzed organs. Animals belonging to GI showed a faster skin wound healing in comparison to the other groups. Animals from GII, however, showed a delayed wound healing process and exhibited lung and microcirculatory alterations. These findings allow us to conclude that the exposure time to the oxygen in hyperbaric environment is crucial and can help or disturb skin wound healing or even be deleterious to other organs.
Collapse
Affiliation(s)
| | - A. Krause
- Universidade Federal de Santa Maria, Brazil
| | | | - Á.J.C. Silva
- National Autonomous University of Nicaragua, Nicaragua
| | - M.A. Inkelmann
- Universidade Regional do Noroeste do Estado do Rio Grande do Sul, Brazil
| | | |
Collapse
|
18
|
Diel R, Schaberg T, Nienhaus A, Otto-Knapp R, Kneitz C, Krause A, Fabri M, Mrowietz U, Bauer T, Häcker B. Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals. Pneumologie 2021; 75:293-303. [PMID: 33598901 DOI: 10.1055/a-1294-1580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND While the risk of tuberculosis (TB) reactivation is adequately documented in relation to TNF-alpha inhibitors (TNFi), the question of what the tuberculosis risk is for newer, non-TNF biologics (non-TNFi) has not been thoroughly addressed. METHODS We conducted a systematic review of randomized phase 2 and phase 3 studies, and long-term extensions of same, published through March 2019. Of interest was information pertaining to screening and treating of latent tuberculosis (LTBI) in association with the use of 12 particular non-TNFi. Only rituximab was excluded. We searched MEDLINE and the ClinicalTrial.gov database for any and all candidate studies meeting these criteria. RESULTS 677 citations were retrieved; 127 studies comprising a total of 34,293 patients who received non-TNFi were eligible for evaluation. Only 80 out of the 127 studies, or 63 %, captured active TB (or at least opportunistic diseases) as potential outcomes and 25 TB cases were reported. More than two thirds of publications (86/127, 68 %) mentioned LTBI screening prior to inclusion of study participants in the respective trial, whereas in only 4 studies LTBI screening was explicitly considered redundant. In 21 studies, patients with LTBI were generally excluded from the trials and in 42 out of the 127 trials, or 33 %, latently infected patients were reported to receive preventive therapy (PT) at least 3 weeks prior to non-TNFi treatment. CONCLUSIONS The lack of information in many non-TNFi studies on the number of patients with LTBI who were either excluded prior to participating or had been offered PT hampers assessment of the actual TB risk when applying the novel biologics. Therefore, in case of insufficient information about drugs or drug classes, the existing recommendations of the German Central Committee against Tuberculosis should be applied in the same way as is done prior to administering TNFi. Well designed, long-term "real world" register studies on TB progression risk in relation to individual substances for IGRA-positive cases without prior or concomitant PT may help to reduce selection bias and to achieve valid conclusions in the future.
Collapse
Affiliation(s)
- R Diel
- Institute for Epidemiology, University Medical Hospital Schleswig-Holstein, Campus Kiel, Germany. Member of the German Center for Lung Research (ARCN).,LungClinic Grosshansdorf, Germany. Airway Research Center North (ARCN), German Center for Lung Research (DZL).,German Central Committee against Tuberculosis, Berlin, Germany
| | - T Schaberg
- German Central Committee against Tuberculosis, Berlin, Germany
| | - A Nienhaus
- Institution for Statutory Accident Insurance and Prevention in the Health and Welfare Services (BGW), Hamburg, Germany.,Institute for Health Service Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - R Otto-Knapp
- German Central Committee against Tuberculosis, Berlin, Germany
| | - C Kneitz
- Medicine, Rheumatology, rheumatological main practice Schwerin, Germany
| | - A Krause
- Department of Rheumatology, Clinical Immunology and Osteology, Immanuel Hospital Berlin, Germany
| | - M Fabri
- Department of Dermatology, University of Cologne, Germany
| | - U Mrowietz
- Psoriasis Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany
| | - T Bauer
- German Central Committee against Tuberculosis, Berlin, Germany
| | - B Häcker
- German Central Committee against Tuberculosis, Berlin, Germany
| |
Collapse
|
19
|
Lakomek HJ, Krause A, Braun J, Hellmich B, Klass M, Lorenz H, Schneider M, Schulze-Koops H, Specker C. [Future of acute inpatient rheumatology in Germany : Statement of the Boards of the German Society for Rheumatology and the Association of Rheumatological Acute Clinics on hospital planning North-Rhine/Westphalia 2019 for the discipline rheumatology]. Z Rheumatol 2020; 80:103-106. [PMID: 33313964 PMCID: PMC7872996 DOI: 10.1007/s00393-020-00939-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/09/2020] [Indexed: 12/03/2022]
Abstract
Im September 2019 wurde vom Ministerium für Arbeit, Gesundheit und Soziales (MAGS) in NRW ein Gutachten zur Krankenhausplanung veröffentlicht. Hierin wurde eine grundlegende Reform der Krankenhausplanung empfohlen, indem zukünftig eine Bedarfsplanung auf der Grundlage einer detaillierten Ausweisung von Leistungsbereichen und Leistungsgruppen erfolgen soll. Nach Aufforderung durch das MAGS NRW hat auch die Deutsche Gesellschaft für Rheumatologie (DGRh) mit Unterstützung des Verbandes Rheumatologischer Akutkliniken (VRA) hierzu Stellung genommen.
Collapse
Affiliation(s)
- H-J Lakomek
- Universitätsklinik für Geriatrie, Mühlenkreiskliniken, Johannes Wesling Klinikum Minden, Hans-Nolte-Str. 1, 32429, Minden, Deutschland.
| | - A Krause
- Abteilung Rheumatologie, Klinische Immunologie und Osteologie, Immanuel Krankenhaus Berlin, Berlin, Deutschland
| | - J Braun
- Rheumazentrum Ruhrgebiet und Ruhr-Universität Bochum, Herne, Deutschland
| | - B Hellmich
- Vaskulitiszentrum Süd, Klinik für Innere Medizin, Rheumatologie und Immunologie, Medius Kliniken - Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim u. Teck, Deutschland
| | - M Klass
- Klinik für Rheumatologie und Physikalische Therapie, Helios St. Johannes Klinik, Duisburg, Deutschland
| | - H Lorenz
- Sektion Rheumatologie, Med. Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.,ACURA-Rheumazentrum Baden-Baden, Baden-Baden, Deutschland
| | - M Schneider
- Poliklinik, Funktionsbereich und Hiller-Forschungszentrum für Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | - H Schulze-Koops
- Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik IV, Ludwig-Maximilians-Universität München, München, Deutschland
| | - C Specker
- Klinik für Rheumatologie und Klinische Immunologie, Evang. Krankenhaus Essen-Werden, Kliniken Essen-Mitte, Essen, Deutschland
| |
Collapse
|
20
|
Lorenz HM, Aringer M, Braun J, Hoyer BF, Krause A, Meyer-Olson D, Mucke J, Rudwaleit M, Schneider M, Sewerin P, Späthling-Mestekemper S, Specker C, Voormann A, Wagner U, Wendler J, Schulze-Koops H. [Mission statement from rheumatologists in the German Society of Rheumatology (DGRh e. V.) : We live rheumatology. German version]. Z Rheumatol 2020; 79:1018-1021. [PMID: 33216190 DOI: 10.1007/s00393-020-00919-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/09/2020] [Indexed: 11/24/2022]
Abstract
Systemic disease demands systemic thinkers. In this mission statement we define rheumatology, describe the role of the German Society of Rheumatology and the rheumatologist's spirit to their discipline. Rheumatologists are dedicated to improving the quality of life of their acute, chronic, and rehabilitative patients on the basis of up to date evidence and strong physician-patient relations. We think, act and interact systemically, scientifically, consistently, transparently, reliably, inclusively, innovatively and enthusiastically.
Collapse
Affiliation(s)
- H-M Lorenz
- Vorstand der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland. .,Ad-hoc-Kommission der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland. .,Sektion Rheumatologie, Medizinische Klinik V, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland.
| | - M Aringer
- Ad-hoc-Kommission der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Bereich Rheumatologie, Medizinische Klinik und Poliklinik III, Universitätsklinikum und Medizinische Fakultät Carl Gustav Carus, TU Dresden, Dresden, Deutschland
| | - J Braun
- Vorstand der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Rheumazentrum Ruhrgebiet, Lehrstuhl für Rheumatologie, Ruhr Universität Bochum, Herne, Deutschland
| | - B F Hoyer
- Ad-hoc-Kommission der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Abteilung für Rheumatologie und klin. Immunologie, 1. Medizinische Klinik, Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Deutschland
| | - A Krause
- Vorstand der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Abteilung für Rheumatologie, Klinische Immunologie und Osteologie, Immanuel Krankenhaus Berlin, Berlin, Deutschland
| | - D Meyer-Olson
- Ad-hoc-Kommission der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Abteilung Rheumatologie/Innere Medizin, m&i Fachklinik Bad Pyrmont und MVZ Weserbergland, Bad Pyrmont, Deutschland.,Klinik für Rheumatologie und Immunologie, Medizinische Hochschule Hannover, Hannover, Deutschland
| | - J Mucke
- Ad-hoc-Kommission der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Poliklinik, Funktionsbereich und Hiller Forschungszentrum für Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | - M Rudwaleit
- Ad-hoc-Kommission der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Klinik für Innere Medizin und Rheumatologie, Klinikum Bielefeld, Bielefeld, Deutschland
| | - M Schneider
- Ad-hoc-Kommission der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Poliklinik, Funktionsbereich und Hiller Forschungszentrum für Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | - P Sewerin
- Vorstand der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Ad-hoc-Kommission der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Poliklinik, Funktionsbereich und Hiller Forschungszentrum für Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | - S Späthling-Mestekemper
- Ad-hoc-Kommission der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Rheumapraxis München Pasing, München, Deutschland
| | - C Specker
- Vorstand der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Klinik für Rheumatologie und Klinische Immunologie, Kliniken Essen-Mitte, Essen, Deutschland
| | - A Voormann
- Ad-hoc-Kommission der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Geschäftsstelle der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland
| | - U Wagner
- Vorstand der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Abteilung für Rheumatologie, Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie, Universitätsklinikum Leipzig, Leipzig, Deutschland
| | - J Wendler
- Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Deutschland
| | - H Schulze-Koops
- Vorstand der Deutschen Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität München, München, Deutschland
| |
Collapse
|
21
|
Affiliation(s)
- A Krause
- Abteilung Rheumatologie, Klinische Immunologie und Osteologie, Immanuel Krankenhaus Berlin, Königstraße 63, 14109, Berlin, Deutschland.
| | - K Krüger
- Rheumatologisches Praxiszentrum, München, Deutschland
| | - J Braun
- Rheumazentrum Ruhrgebiet und Ruhr-Universität Bochum, Herne, Deutschland
| | - G Gauler
- Rheumapraxis an der Hase, Osnabrück, Deutschland
| | - K Hoeper
- Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover, Hannover, Deutschland
| | - F Schuch
- Internistische Praxisgemeinschaft Rheumatologie - Nephrologie, Erlangen, Deutschland
| | - A J Voormann
- Deutsche Gesellschaft für Rheumatologie, Berlin, Deutschland
| |
Collapse
|
22
|
Abstract
Modern rheumatology enables better and earlier diagnosis and therapy of inflammatory rheumatic system diseases. At the same time, the requirements for the care of rheumatologic patients have risen considerably for non-medical assistant professions and specialists for nursing professions. Since 2006 there has been established an education curriculum "Rheumatological Specialist Assistant DGRh-BDRh" (RFA) with the training to become a "Rheumatological Specialist Assistant (DGRh-BDRh)". In Europe and in parallel in Germany, assistant professions are increasingly involved in the early detection and care of patients with rheumatic diseases and entrusted with tasks.In this work, the overarching principles for delegation of medical tasks to RFA and recommendations for the delegation are published by the Commission for Delegation of the German Society for Rheumatology (DGRh). These recommendations are based on the requirements of the German Medical Association and have been legally evaluated. With the extension of the training of the RFA board certification is aimed for "MFA for Rheumatology". These recommendations enable more transparency and security for delegating doctors and the delegated RFA's.
Collapse
Affiliation(s)
- A Krause
- Klinik für Innere Medizin, Abteilung Rheumatologie, Klinische Immunologie und Osteologie, Immanuel Krankenhaus Berlin, Königstr. 63, 14109, Berlin, Deutschland.
| | - F Schuch
- Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Deutschland
| | - J Braun
- Rheumazentrum Ruhrgebiet, Lehrstuhl für Rheumatologie, Ruhr Universität Bochum, Bochum, Deutschland
| | - G Gauler
- Rheumapraxis, Else Brandström Str., Osnabrück, Deutschland
| | - K Hoeper
- Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover, Hannover, Deutschland
| | - K Krüger
- Praxiszentrum St. Bonifatius, München, Deutschland
| | - M Wallhäuser
- PPP Rechtsanwälte, Bergisch Gladbach, Deutschland
| | - A J Voormann
- Dt. Gesellschaft für Rheumatologie, Berlin, Deutschland
| |
Collapse
|
23
|
Weiß K, Schmidt WA, Krause A, Schäfer VS. AB1129 PREVALENCE OF FINDINGS IN ROUTINE ABDOMINAL ULTRASOUND IN PATIENTS WITH CONNECTIVE TISSUE DISEASES AND THEIR IMPACT ON DISEASE MANAGEMENT. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Patients with connective tissue diseases (CTD) are often screened for abdominal organ involvement with ultrasound.Objectives:To analyse the prevalence of routine abdominal ultrasound findings in different CTD entities and their impact on therapeutic decisions.Methods:Retrospective chart review of all in-patients from a tertiary rheumatological referral center with CTD diagnosis and abdominal ultrasound examination between January 1st 2006 and December 31st 2015. Descriptive statistics were used to describe patient characteristics and frequencies of ultrasound findings. To determine whether findings impacted therapeutic decisions, we analysed if they were discussed in the hospital discharge letter.Results:1.092 patients with a total of 1.695 hospitalizations were analysed. Mean age was 55.1 years (range: 17-90 years, SD: 15.8), mean disease duration was 6.4 years (range: 0.0-52.8 years, SD: 9.1). 87.5 % were female.Table 1 shows the frequency of findings per CTD entity. 48 out of all 1.695 examinations were discussed in the hospital discharge letter. In 30 cases, the physician described the ultrasound results as pivotal for therapeutic decision-making.Table 1.Frequency of abdominal ultrasound findings in different CTD.All patientsSLESjögren´s syndromeSystemic sclerosisMyositisUCTDMCTDprimarysecon-darydiffuselimitedwith myositisPMDMNumber of patients (females)1092 (956)194 (172)252 (236)167 (156)78(63)125 (116)17(11)24 (11)33 (24)99(81)87(72)Frequency of findings (%)GallbladderConcrements8.26.710.77.210.3-5.916.712.16.15.7Wall thickening0.5-0.41.2-----2.0-Status post cholecystectomy14.48.817.920.414.117.65.925.03.014.15.7PancreasPancreatic lipomatosis14.310.811.125.115.412.023.525.015.214.13.4Inhomogeneous parenchyma1.92.61.6--0.8-4.26.13.04.6Pancreatitis0.20.5-0.6-------Lesion/tumor0.5-0.4-1.31.6-4.2---KidneysAltered echogenity4.75.76.04.27.74.8-8.36.1-2.3Hydronephrosis2.21.52.41.26.43.2-8.33.0-1.1Cyst10.39.310.712.615.49.65.94.215.28.14.6Concrements2.52.12.83.03.82.45.94.2-1.02.3Lesion/tumor0.60.50.8-3.8---3.0--Abbreviations: SLE: systemic lupus erythematosus, PM: polymyositis, DM: dermatomyositis, UCTD: undifferentiated connective tissue disease, MCTD: mixed connective tissue disease. “ - “ signifies 0.0% (n=0).Table 2.Frequency of abdominal ultrasound findings in different CTD.Conclusion:Routinely performed abdominal ultrasound rarely yields disease specific findings which subsequently impact the therapeutic decision-making process.Disclosure of Interests:None declared
Collapse
|
24
|
Regierer A, Hasseli R, Hoyer B, Krause A, Lorenz HM, Pfeil A, Richter J, Schmeiser T, Specker C, Strangfeld A, Voll R, Schulze-Koops H, Müller-Ladner U. CO0004 OLDER AGE, CARDIOVASCULAR COMORBIDITY AND GLUCOCORTICOSTEROIDS ARE RISK FACTORS FOR COVID-19 HOSPITALISATION IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: FIRST RESULTS OF THE GERMAN COVID-19-IRD REGISTRY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.6833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Patients with inflammatory rheumatic diseases (IRD) and infection with SARS-CoV-2 may be at risk to develop a severe course of COVID-19. To gather knowledge about SARS-CoV-2 infections in IRD patients, a national registry was established to elucidate IRD specific profiles of COVID-19.Objectives:To identify risk factors for hospitalisation.Methods:Patients from the German registry on SARS-CoV-2 infection in IRD were analysed. Patients are enrolled with a pre-existing IRD and a positive lab-result for a SARS-CoV-2 infection. The main outcome parameter was hospitalisation versus non-hospitalisation. Multivariable logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Covariates included in the model were age group, gender, key comorbidities (cardiovascular, lung diseases, chronic renal insufficiency), prior and/or current use of glucocorticosteroids (GC) or NSAIDs and remission.Results:Until May 17th, 2020, data from 192 IRD patients with SARS-CoV-2 infection were reported (67 males; 124 females; 1 diverse). 64 patients were hospitalised, 21 patients were ventilated non-invasively/invasively and 15 patients died.Baseline characteristics are shown in table 1, stratified into the patient groups non-hospitalisation, hospitalisation without ventilation, and hospitalisation with ventilation. Non-hospitalised patients were younger, had less comorbidities and were less often treated with GC. In the group of hospitalised patients compared to non-hospitalised patients more patients were male (42% vs 32% male) with an even higher proportion in the ventilated patient group (57% male).In the multivariable logistic regression model, age>65 years (OR 5.1; 95%CI 2.3-11.4), cardiovascular comorbidity (OR 2.3; 95%CI 1.0-5.0), and prior and/or current treatment with GC (OR 2.6; 95%CI 1.2-5.4) were independently associated with hospitalisation.Parameter, N (%)Non-hospitalisation128 (66.7)Hosp. without ventilation42 (22.4)Hosp. with ventilation21 (10.9)Age [years], mean (SD)53.8 (13.4)65.2 (15.5)69.7 (9.9)Female87 (68.5)28 (65.1)9 (42.9)RA60 (46.9)24 (55.8)12 (57.1)Psoriasis23 (18)3 (7)3 (14.3)Axial spondyloarthritis14 (10.9)2 (4.7)0Lupus7 (5.5)1 (2.3)0Remission of IRD67 (52.3)23 (53.5)4 (19)Number of comorbidities, mean (SD)1 (1.2)1.8 (1.4)2.4 (1.5)Cardiovascular disease42 (32.8)25 (58.1)16 (76.2)Pulmonary disease16 (12.5)8 (18.6)8 (38.1)Chronic renal insufficiency5 (3.9)7 (16.3)4 (19)Cancer2 (1.6)4 (9.3)2 (9.5)Obesity (BMI>30)23 (18)5 (11.6)3 (14.3)Diabetes3 (2.3)7 (16.3)4 (19)Other comorbidities20 (15.6)9 (20.9)6 (28.6)csDMARD (without HCQ)59 (46.1)25 (58.1)8 (38.1)HCQ13 (10.2)1 (2.3)2 (9.5)bDMARD48 (37.5)15 (34.9)8 (38.1)tsDMARD5 (3.9)1 (2.3)1 (4.8)Glucocorticosteroids47 (37)29 (67.4)13 (61.9)NSAIDs21 (16.4)5 (11.6)1 (4.8)Conclusion:As has been described for COVID-19 in general, also in IRD male gender may be associated with a more severe course of the infection as the descriptive analysis of data shows. Risk factors for SARS-CoV-2 infection-dependent hospitalisation in IRD patients include age (>65 years), cardiovascular comorbidities, and prior and/or current treatment with GC.Disclosure of Interests:Anne Regierer Speakers bureau: Novartis, Celgene, Janssen-Cilag, Rebecca Hasseli Grant/research support from: Pfizer, Consultant of: Pfizer, Gilead, Novartis, Celgene, Abbvie, Medac, Bimba Hoyer: None declared, Andreas Krause: None declared, Hanns-Martin Lorenz Grant/research support from: Consultancy and/or speaker fees and/or travel reimbursements: Abbvie, MSD, BMS, Pfizer, Celgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, Astra-Zeneca, Lilly. Scientific support and/or educational seminars and/or clinical studies: Abbvie, MSD, BMS, Pfizer, Celgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, Astra-Zeneca, Lilly, Baxter, SOBI, Biogen, Actelion, Bayer Vital, Shire, Octapharm, Sanofi, Hexal, Mundipharm, Thermo Fisher., Consultant of: see above, Alexander Pfeil Grant/research support from: This study Investigator Initiated Study “Automatic assessment of joint space narrowing in rheumatoid arthritis based on the Post-hoc analysis” (number: IIS-2016-110818) is a part of the of the Investigator Initiated Study “The quantification of inflammatory related periarticular bone loss in certolizumab pegol treated patients with rheumatoid arthritis” (number: IIS-2014-101458) which is supported by UCB Pharma GmbH, Monheim, Germany., Jutta Richter Grant/research support from: Grant/research support from: GlaxoSmithKline and UCB Pharma for performing the LuLa-study., Tim Schmeiser Speakers bureau: Actelion, UCB, Pfizer, Christof Specker Consultant of: Abbvie, Boehringer Ingelheim, Chugai, Lilly, Novartis, Sobi, UCB, Celgene, Janssen-Cilag, MSD, Pfizer, Roche, UCB, Toshiba, Anja Strangfeld Speakers bureau: AbbVie, BMS, Pfizer, Roche, Sanofi-Aventis, Reinhard Voll: None declared, Hendrik Schulze-Koops: None declared, Ulf Müller-Ladner Speakers bureau: Biogen
Collapse
|
25
|
Schulze-Koops H, Holle J, Moosig F, Specker C, Aries P, Burmester G, Fiehn C, Hoyer B, Krause A, Leipe J, Lorenz HM, Schneider M, Sewerin P, Voormann A, Wager U, Krüger K, Iking-Konert C. [Current guidance of the German Society of Rheumatology for the care of patients with rheumatic diseases during the SARS-CoV-2/Covid 19 pandemic]. Z Rheumatol 2020; 79:385-388. [PMID: 32342184 PMCID: PMC7184809 DOI: 10.1007/s00393-020-00799-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
In der aktuellen SARS-CoV-2 Pandemie bestehen viele Fragen mit Blick auf die sichere Behandlung von Patienten mit entzündlich-rheumatischen Erkrankungen. Auf viele dieser Fragen gibt es zur Zeit noch keine evidenzbasierte Antwort und das macht die Betreuung der Patienten nicht leicht. Die Deutsche Gesellschaft für Rheumatologie e. V. (DGRh) will mit diesen ersten Empfehlungen Hilfestellung für spezielle Belange in der Betreuung von Rheumapatienten angesichts der aktuellen Bedrohung durch SARS-CoV-2 geben. Um den dynamischen weltweiten Erkenntnisgewinn für unsere Patienten zu nutzen, werden die Empfehlungen regelmäßig aktualisiert. Die aktualisierten Versionen der Empfehlungen werden auf der Homepage der DGRh hinterlegt.
Collapse
Affiliation(s)
- H Schulze-Koops
- Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland. .,Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik IV, Ludwig-Maximilians-Universität München, Pettenkoferstraße 8a, München, Deutschland.
| | - J Holle
- Rheumazentrum Schleswig-Holstein Mitte, Neumünster, Deutschland
| | - F Moosig
- Rheumazentrum Schleswig-Holstein Mitte, Neumünster, Deutschland
| | - C Specker
- Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Klinik für Rheumatologie und Klinische Immunologie, Kliniken Essen-Mitte, Essen, Deutschland
| | - P Aries
- Rheumatologie im Struenseehaus, Hamburg, Deutschland
| | - G Burmester
- Klinik für Rheumatologie und Klinische Immunologie, Charité - Universitäts Medizin Berlin, Freie Universität und Humboldt Universität Berlin, Berlin, Deutschland
| | - C Fiehn
- Medical Center Baden-Baden und ViDia-Kliniken Karlsruhe, Praxis für Rheumatologie und Klinische Immunologie, Baden-Baden, Deutschland
| | - B Hoyer
- Abteilung für Rheumatologie, 1. Medizinische Klinik, Universitätskrankenhaus Schleswig-Holstein Campus Kiel, Kiel, Deutschland
| | - A Krause
- Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Abteilung für Rheumatologie, Osteologie und Klinische Immunologie, Immanuel Krankenhaus Berlin, Berlin, Deutschland
| | - J Leipe
- Abteilung für Rheumatologie, Medizinische Klinik V, Universitätskrankenhaus Mannheim, Mannheim, Deutschland
| | - H-M Lorenz
- Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Abteilung für Rheumatologie, Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | - M Schneider
- Poliklinik, Funktionsbereich und Hiller Forschungszentrum für Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | - P Sewerin
- Poliklinik, Funktionsbereich und Hiller Forschungszentrum für Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | - A Voormann
- Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland
| | - U Wager
- Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Abteilung für Rheumatologie, Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie, Universitätsklinikum Leipzig, Leipzig, Deutschland
| | - K Krüger
- Rheumatologisches Praxiszentrum, Kommission Pharmakotherapie der DGRh e. V., St. Bonifatius-Straße 5, 81541, München, Deutschland.
| | - C Iking-Konert
- III. Medizinische Klinik und Poliklinik Sektion Rheumatologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland
| | | |
Collapse
|
26
|
Krause A, Aries PM, Berger S, Fiehn C, Kellner H, Lorenz HM, Meier L, Müller GA, Müller-Ladner U, Schwarting A, Tony HP, Peters MA, Wendler J. Rituximab in routine care of severe active rheumatoid arthritis : A prospective, non-interventional study in Germany. Z Rheumatol 2019; 78:881-888. [PMID: 30276727 DOI: 10.1007/s00393-018-0552-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
OBJECTIVE To assess safety, effectiveness and onset of effect of rituximab (RTX) in routine clinical treatment of severe, active rheumatoid arthritis (RA). METHODS Prospective, multi-centre, non-interventional study in rheumatological outpatient clinics or private practices in Germany. RTX-naïve adult patients were to receive RTX according to marketing authorisation and at their physician's discretion. Also according to their physician's discretion, patients could receive a second cycle of RTX (re-treatment = treatment continuation). Major outcome was the change in Disease Activity Score based on 28-joints count and erythrocyte sedimentation rate (DAS28-ESR) over 24 weeks and during 6 months of re-treatment. RESULTS Overall, 1653 patients received at least one cycle RTX; 99.2% of these had received disease-modifying antirheumatic drugs (DMARD) pre-treatment and 75.5% anti-tumor necrosis factor(TNF)‑α pre-treatment. After a mean interval of 8.0 months, 820 patients received RTX re-treatment. Mean DAS28-ESR decreased from 5.3 at baseline to 3.8 after 24 weeks (-1.5 [95% confidence interval, CI: -1.6; -1.4]), and from 4.1 at start of cycle 2 to 3.5 at study end (change from baseline: -1.8 [95% CI: -2.0; -1.7]). Improvements in DAS28-ESR and Health Assessment Questionnaire (HAQ) score occurred mainly during the first 12 weeks of RTX treatment, with further DAS28-ESR improvement until week 24 or month 6 of re-treatment. Improvements in DAS28-ESR and EULAR responses were more pronounced in seropositive patients. RF was a predictor of DAS28-ESR change to study end. Safety analysis showed the established profile of RTX. CONCLUSION RTX was safe and effective in a real-life setting with rapid and sustained improvement in RA signs and symptoms.
Collapse
Affiliation(s)
- A Krause
- Abteilung Rheumatologie und Klinische Immunologie, Klinik für Innere Medizin, Immanuel Krankenhaus, Königstraße 63, 14109, Berlin, Germany.
| | - P M Aries
- Rheumatologie im Struenseehaus, Hamburg, Germany
| | - S Berger
- Private Practice, Naunhof, Germany
| | - C Fiehn
- Praxis für Rheumatologie und klinische Immunologie, Baden-Baden, Germany
| | - H Kellner
- Private Practice and Division of Rheumatology, KH Neuwittelsbach, Munich, Germany
| | - H-M Lorenz
- Division of Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
| | - L Meier
- RheumaPraxis, Hofheim, Germany
| | - G A Müller
- Department of Nephrology and Rheumatology, University Hospital Göttingen, Göttingen, Germany
| | - U Müller-Ladner
- Department of Rheumatology and Clinical Immunology, Kerckhoff Hospital GmbH, Bad Nauheim, Germany
| | - A Schwarting
- First Department of Medicine, University Hospital, Johannes Gutenberg-University, Mainz, Germany
| | - H-P Tony
- Division of Clinical Immunology/Rheumatology, Department of Internal Medicine II, University of Würzburg, Würzburg, Germany
| | - M A Peters
- Medical Management Rheumatology, Roche Pharma AG, Grenzach-Wyhlen, Germany
| | | |
Collapse
|
27
|
Benesova K, Lorenz HM, Lion V, Voigt A, Krause A, Sander O, Schneider M, Feuchtenberger M, Nigg A, Leipe J, Briem S, Tiessen E, Haas F, Rihl M, Meyer-Olson D, Baraliakos X, Braun J, Schwarting A, Dreher M, Witte T, Assmann G, Hoeper K, Schmidt RE, Bartz-Bazzanella P, Gaubitz M, Specker C. [Early recognition and screening consultation: a necessary way to improve early detection and treatment in rheumatology? : Overview of the early recognition and screening consultation models for rheumatic and musculoskeletal diseases in Germany]. Z Rheumatol 2019; 78:722-742. [PMID: 31468170 DOI: 10.1007/s00393-019-0683-y] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
In order to reduce the prognostically relevant time interval between the initial manifestation of a rheumatic and musculoskeletal disease and diagnosis as well as the consecutive initiation of an appropriate treatment, several rheumatological centers in Germany have improved the access to initial rheumatologic evaluation by establishing early recognition/screening clinics at their respective sites. Corresponding models located at Altoetting·Burghausen, Bad Pyrmont, Berlin Buch, Duesseldorf, Heidelberg, Herne, Mannheim as well as supraregional/multicenter initiatives Rheuma Rapid, RhePort and Rheuma-VOR are presented in this overview along with the respective characteristics, potential advantages and disadvantages, but also first evaluation results of several models. The aim of this publication is to promote early detection of rheumatic and musculoskeletal diseases as one of the most important challenges in current rheumatology by encouraging further rheumatologic centers and practices to launch their own early recognition/screening consultation model on the basis of aspects presented herein.
Collapse
Affiliation(s)
- K Benesova
- Sektion Rheumatologie, Innere Medizin V, Universitätsklinik Heidelberg, Heidelberg, Deutschland.
| | - H-M Lorenz
- Sektion Rheumatologie, Innere Medizin V, Universitätsklinik Heidelberg, Heidelberg, Deutschland.,ACURA Rheumazentrum Baden-Baden, Baden-Baden, Deutschland
| | - V Lion
- Sektion Rheumatologie, Innere Medizin V, Universitätsklinik Heidelberg, Heidelberg, Deutschland
| | - A Voigt
- Abteilung Rheumatologie, klinische Immunologie und Osteologie, Standort Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Deutschland
| | - A Krause
- Abteilung Rheumatologie, klinische Immunologie und Osteologie, Standort Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Deutschland
| | - O Sander
- Poliklinik und Funktionsbereich für Rheumatologie & Hiller Forschungszentrum Rheumatologie, UKD Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | - M Schneider
- Poliklinik und Funktionsbereich für Rheumatologie & Hiller Forschungszentrum Rheumatologie, UKD Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | | | - A Nigg
- MVZ MED
- BAYERN OST Altötting·Burghausen, Burghausen, Deutschland
| | - J Leipe
- Sektion Rheumatologie, V. Medizinische Klinik, Universitätsklinik Mannheim, Mannheim, Deutschland
| | - S Briem
- Innere Medizin und Rheumatologie, Alb-Donau Klinikum Langenau, Langenau, Deutschland
| | - E Tiessen
- Innere Medizin und Rheumatologie, Alb-Donau Klinikum Langenau, Langenau, Deutschland
| | - F Haas
- Rheumatologische Facharztpraxis, Tübingen, Deutschland
| | - M Rihl
- Rheumatologische Schwerpunktpraxis, Traunstein, Deutschland
| | - D Meyer-Olson
- m&i Fachklinik Bad Pyrmont und MVZ Weserbergland, Bad Pyrmont, Deutschland
| | - X Baraliakos
- Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Bochum, Deutschland
| | - J Braun
- Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Bochum, Deutschland
| | - A Schwarting
- Schwerpunkt Rheumatologie und klinische Immunologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland.,ACURA Rheumakliniken Rheinland-Pfalz GmbH, Bad Kreuznach, Deutschland
| | - M Dreher
- Schwerpunkt Rheumatologie und klinische Immunologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland
| | - T Witte
- Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover, Hannover, Deutschland
| | - G Assmann
- Rheumatologie, Universitätsklinikum des Saarlandes, Homburg, Deutschland
| | - K Hoeper
- Regionales Kooperatives Rheumazentrum Niedersachsen e. V., Hannover, Deutschland
| | - R E Schmidt
- Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover, Hannover, Deutschland
| | - P Bartz-Bazzanella
- Klinik für Internistische Rheumatologie, Rhein-Maas Klinikum, Würselen, Deutschland
| | - M Gaubitz
- Interdisziplinäre Diagnostik und Therapie - Akademie für Manuelle Medizin, WWU Münster, Münster, Deutschland
| | - C Specker
- Klinik für Rheumatologie und Klinische Immunologie, Evang. Krankenhaus Essen-Werden, Kliniken Essen-Mitte, Essen, Deutschland
| |
Collapse
|
28
|
Abstract
Rheumatoid arthritis (RA) is one of the most frequent chronic inflammatory rheumatic diseases and when untreated leads to chronic tissue destruction and increased mortality. Due to innovative systemic treatment strategies established over the last 20-25 years, the prognosis has considerably improved in terms of disease and socioeconomic burdens, symptoms, long-term prognosis, ability to work and mortality; however, as a rule a prerequisite is long-term and continuous treatment. A medicinal cure of RA is still not in view. For many patients this means the long-term use of very expensive medications. In addition to hemato-oncology, rheumatology has become the second most expensive discipline in Germany in terms of cost per patient. Convincing data from many studies imply that an early start of treatment within the first few weeks after clinical onset of symptoms improves the prognosis, reduces the necessity for expensive drugs and thereby considerably decreases medical costs. This results in the requirement that every patient with symptoms of arthritis must be seen by a rheumatologist within the first 6 weeks following initial manifestation of the disease. Such an improvement in treatment can only be achieved in Germany if the numbers of rheumatologists and trained healthcare professionals in practices such as clinics are considerably increased. This is not only in the interests of patients but also in the interests of the health insurance companies because the investment in the healthcare infrastructure with internistic rheumatologists will result in substantial economic benefits for the cost bearer. It must be the common task of all players in healthcare policy, cost bearers and internistic rheumatologists to provide optimal conditions in medical as well as economical terms.
Collapse
Affiliation(s)
- H-M Lorenz
- Klinik für Hämatologie, Onkologie und Rheumatologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland.
| | - J Wendler
- Internistische Praxisgemeinschaft Rheumatologie - Nephrologie, Erlangen, Deutschland
| | - A Krause
- Klinik für Rheumatologie und Klinische Immunologie, Immanuel Krankenhaus Berlin, Berlin, Deutschland
| |
Collapse
|
29
|
Abstract
Pulmonary involvement in patients with rheumatoid arthritis, in particular interstitial lung diseases (RA-ILD) is of great clinical importance. Patients should be asked about symptoms of pulmonary involvement and the lungs should be clinically examined even during the diagnostic procedure and regularly during the course of the disease. Before initiation of a basic pharmacological treatment an X‑ray examination of thoracic organs is obligatory. In cases of conspicuous clinical or radiological findings, extended diagnostic procedures with lung function testing (body plethysmography with diffusion measurement) and high resolution computed tomography (CT) should be performed, depending on the findings. The differential diagnosis of interstitial lung alterations in patients with RA is broad and should consider side effects of the basis medication in addition to infectious causes. The optimal pharmacological treatment of RA-ILD is not sufficiently clarified. The value of methotrexate (MTX) has changed because, in contrast to previous assumptions, a better course could be observed under MTX treatment, at least in mild to moderate courses of RA-ILD. In the case of a clinically relevant RA-ILD, tumor necrosis factor (TNF) blockers should be avoided because a dramatic deterioration of pulmonary function has sometimes been observed. Among biological disease-modifying antirheumatic drugs (DMARD), rituximab and abatacept are currently preferred. The role of Janus kinase (JAK) inhibitors in RA-ILD is currently being discussed but limited data are available. Patients with RA-ILD benefit from a close collaboration between pulmonologists and rheumatologists.
Collapse
Affiliation(s)
- A Krause
- Klinik für Innere Medizin, Abteilung Rheumatologie, klinische Immunologie und Osteologie, Immanuel Krankenhaus Berlin, Königstr. 63, 14109, Berlin, Deutschland.
| | - A Rubbert-Roth
- Klinik für Rheumatologie, Kantonsspital St. Gallen, St. Gallen, Schweiz
| |
Collapse
|
30
|
Lange AP, Almeida LY, Araújo Silva CL, Scheucher PS, Chahud F, Krause A, Bohlander SK, Rego EM. CCAAT/enhancer-binding protein alpha (CEBPA) gene haploinsufficiency does not alter hematopoiesis or induce leukemia in Lck-CALM/AF10 transgenic mice. ACTA ACUST UNITED AC 2019; 52:e8424. [PMID: 31141090 PMCID: PMC6542091 DOI: 10.1590/1414-431x20198424] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Accepted: 03/15/2019] [Indexed: 12/31/2022]
Abstract
Although rare, CALM/AF10 is a chromosomal rearrangement found in immature T-cell acute lymphoblastic leukemia (T-ALL), acute myeloid leukemia, and mixed phenotype acute leukemia of T/myeloid lineages with poor prognosis. Moreover, this translocation is detected in 50% of T-ALL patients with gamma/delta T cell receptor rearrangement, frequently associated with low expression of transcription factor CCAAT/enhancer-binding protein alpha (CEBPA). However, the relevance of CEBPA low expression for CALM/AF10 leukemogenesis has not yet been evaluated. We generated double mutant mice, which express the Lck-CALM/AF10 fusion gene and are haploinsufficient for the Cebpa gene. To characterize the hematopoiesis, we quantified hematopoietic stem cells, myeloid progenitor cells, megakaryocyte-erythrocyte progenitor cells, common myeloid progenitor cells, and granulocyte-macrophage progenitor cells. No significant difference was detected in any of the progenitor subsets. Finally, we tested if Cebpa haploinsufficiency would lead to the expansion of Mac-1+/B220+/c-Kit+ cells proposed as the CALM/AF10 leukemic progenitor. Less than 1% of bone marrow cells expressed Mac-1, B220, and c-Kit with no significant difference between groups. Our results showed that the reduction of Cebpa gene expression in Lck-CALM/AF10 mice did not affect their hematopoiesis or induce leukemia. Our data corroborated previous studies suggesting that the CALM/AF10 leukemia-initiating cells are early progenitors with lymphoid/myeloid differentiating potential.
Collapse
Affiliation(s)
- A P Lange
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - L Y Almeida
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - C L Araújo Silva
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - P S Scheucher
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - F Chahud
- Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - A Krause
- Laboratório de Análises Clínicas Veterinárias, Universidade Federal de Santa Maria, Santa Maria, RS, Brasil
| | - S K Bohlander
- Leukaemia & Blood Cancer Research Unit, Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand
| | - E M Rego
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Divisão de Hematologia, LIM31, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| |
Collapse
|
31
|
Krause A, Ritzmann R, Lee K, Freyler K, Gollhofer A. Acute Neuromuscular Modulation Enhances Postural Control after Whole-body Vibration. Dtsch Z Sportmed 2019. [DOI: 10.5960/dzsm.2018.357] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
32
|
Chmielowska E, Krause A, Olejniczak M, Swiezynski M, Kopec J. P3.01-17 Long Survivors with Advanced Lung Cancer - Efficacy and Tolerability of Nivolumab. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Voigt A, Seipelt E, Bastian H, Juche A, Krause A. [Improved early diagnostics of rheumatic diseases : Monocentric experiences with an open rheumatological specialist consultation]. Z Rheumatol 2018; 77:844-849. [PMID: 30255411 DOI: 10.1007/s00393-018-0540-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
AIM OF THE PROJECT To establish an open rheumatological outpatient consultation service for early diagnosis of inflammatory rheumatic diseases and initiation of further diagnostics and treatment. METHODS In 2015 an open consultation service was initiated for patients with signs of an early rheumatic disease after referral by primary care physicians. Patients could attend once a week without the need for a prior appointment if they fulfilled at least one of the following criteria: positive rheumatoid factor, increased CRP, anti-CCP antibody or antinuclear antibody, joint pain or back pain for over 3 months, swollen joints, fever of unknown origin or acute muscle pain with or without headache of unknown origin. This article presents the results of the retrospective descriptive data analysis of the first 2 years of this project. RESULTS A total of 1262 patients were treated with an average of approximately 20 patients per consultation. In nearly half of the patients an inflammatory rheumatological disease could be diagnosed and immediate diagnostic and treatment measures could be initiated. The diagnostic delay for patients with rheumatoid arthritis was 12 weeks, for patients with polymyalgia rheumatica 11 weeks and for patients with psoriatic arthritis or axial spondylarthritis 18 and 44 weeks, respectively. The time expenditure was a total of 4-5 h per week for an experienced rheumatologist and a specialized rheumatology nurse. CONCLUSION Through this open rheumatological outpatient consultation a low threshold opportunity for the early diagnosis of rheumatologic diseases could be established. The diagnostic delay for many rheumatological diseases could be considerably shortened. Cooperation with rheumatologists in private practice guaranteed the subsequent specialized rheumatological care of the identified patients in the early stages of their illness.
Collapse
Affiliation(s)
- A Voigt
- Standort Berlin Buch, Immanuel Krankenhaus Berlin, Lindenberger Weg 19, 13125, Berlin, Deutschland.
| | - E Seipelt
- Standort Berlin Buch, Immanuel Krankenhaus Berlin, Lindenberger Weg 19, 13125, Berlin, Deutschland
| | - H Bastian
- Standort Berlin Buch, Immanuel Krankenhaus Berlin, Lindenberger Weg 19, 13125, Berlin, Deutschland
| | - A Juche
- Standort Berlin Buch, Immanuel Krankenhaus Berlin, Lindenberger Weg 19, 13125, Berlin, Deutschland
| | - A Krause
- Standort Berlin Buch, Immanuel Krankenhaus Berlin, Lindenberger Weg 19, 13125, Berlin, Deutschland
| |
Collapse
|
34
|
Gurr J, Luinstra G, Krause A. Neuartige Hybridmaterialien durch katalytische Olefinpolymerisation an Gerüstsubstanzen aus Lignocellulosen. CHEM-ING-TECH 2018. [DOI: 10.1002/cite.201855156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. Gurr
- Universität Hamburg; Institut für Holzwissenschaften; Leuschnerstraße 91 c 21031 Hamburg Deutschland
| | - G. A. Luinstra
- Universität Hamburg; Technische und Makromolekulare Chemie; Bundesstraße 45 20146 Hamburg Deutschland
| | - A. Krause
- Universität Hamburg; Institut für Holzwissenschaften; Leuschnerstraße 91 c 21031 Hamburg Deutschland
| |
Collapse
|
35
|
Feben C, Kromberg J, McDonald A, Krause A. Timely diagnosis of vascular Ehlers Danlos syndrome - the need for genetic testing and counselling. S AFR J SURG 2018. [DOI: 10.17159/2078-5151/2018/v56n3a2440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
36
|
Abstract
INTRODUCTION Quality management (QM) is a control tool for the implementation of a wide range of organizational measures aimed at achieving process orientation and process optimization. The organizational framework for these measures can be structured to fulfill the requirements of certification to the DIN EN ISO 9001 standard. The objective was to implement this tool within a university otorhinolaryngology department. MATERIAL AND METHOD After drawing up a project plan, the measures required to fulfill the audit requirements were put into practice by a QM core team, which included employees from four areas: healthcare, research, nursing and teaching. RESULTS The measures carried out resulted in the achievement of certification, provided that annual surveillance audits are performed. DISCUSSION The attainment of the certificate requires continuous fulfillment of the required standards. Future requirements, such as the demands placed on knowledge management, necessitate further appropriate measures.
Collapse
Affiliation(s)
- M Teschner
- Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
| | - H Voigt
- Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland
| | - S Teschner
- Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland
| | - A Krause
- Stabsstelle Betriebsorganisation, Innovations- und Qualitätsmanagement, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland
| | - T Lenarz
- Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland
| |
Collapse
|
37
|
Krause A, Machacek M, Lott D, Hurst N, Bruderer S, Dingemanse J. Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension. CPT Pharmacometrics Syst Pharmacol 2017; 6:477-485. [PMID: 28556581 PMCID: PMC5529739 DOI: 10.1002/psp4.12202] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Revised: 04/07/2017] [Accepted: 04/10/2017] [Indexed: 12/15/2022]
Abstract
Selexipag (Uptravi) is an oral selective IP prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension (PAH). The pivotal GRIPHON study was the largest clinical study ever conducted in PAH patients, providing long‐term data from 1,156 patients. PAH comedication did not affect exposure to selexipag, while exposure to its active metabolite ACT‐333679 was reduced by 30% when taken in combination, clinically not relevant in the context of individual dose up‐titration. Using log‐linear regression models linking model‐predicted steady‐state exposure to pharmacodynamics (PD), exposure to selexipag and ACT‐333679 showed some statistically significant, albeit not clinically relevant, effects on exercise capacity, laboratory values, and the occurrence of prostacyclin‐related adverse events, but not on vital signs or adverse events denoting hemorrhage. Using suitable modeling techniques, the GRIPHON study yielded clinically relevant data with limited burden of pharmacokinetics (PK) blood sampling, demonstrating that PK/PD modeling enables firm conclusions even with sparse PK and PD sampling.
Collapse
Affiliation(s)
- A Krause
- Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - M Machacek
- Lixoft, Modelling and Pharmacology, Antony, France
| | - D Lott
- Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - N Hurst
- Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - S Bruderer
- Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - J Dingemanse
- Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| |
Collapse
|
38
|
Krause A, Gollhofer A, Freyler K, Jablonka L, Ritzmann R. Acute corticospinal and spinal modulation after whole body vibration. J Musculoskelet Neuronal Interact 2016; 16:327-338. [PMID: 27973385 PMCID: PMC5259574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVES The objective of this study was to investigate neural effects of acute whole body vibration (WBV) on lower limb muscles regarding corticospinal and spinal excitability. METHODS In 44 healthy subjects (16 f/ 28 m), motor evoked potentials (MEP) and H-reflexes in m. soleus (SOL) and gastrocnemius medialis (GM) were elicited before (t1), immediately after (t2), 2 (t3), 4 (t4) and 10 min after (t5) WBV. RESULTS After WBV, MEP amplitudes were significantly increased in SOL (t2+15±30%, t3+22±32%, t4+15±35%, t5+20±30%, P<0.05), but not in GM (t2+32±62%, t3+9±35%, t4+8±36%, t5+22±47%; P=0.07). Contrarily, H-reflexes were significantly reduced in SOL (t2-19±28%, t3-21±22%, t4-20±21%, t5-14±28%, P<0.05) and GM (t2-14±37%, t3-16±25%, t4-18±29%, t5-16±28%, P<0.05). CONCLUSIONS A temporary sustained enhancement of corticospinal excitability concomitant with spinal inhibition after WBV points towards persisting neural modulation in the central nervous system. This could indicate greater neural modulation over M1 and descending pathways, while the contribution of spinal pathways is reduced.
Collapse
Affiliation(s)
- A. Krause
- Department of Sport Science, University of Freiburg, Freiburg, Germany,Corresponding author: Krause Anne, Department of Sport Science, University of Freiburg, Schwarzwaldstraße 175, 79117 Freiburg, Germany E-mail:
| | - A. Gollhofer
- Department of Sport Science, University of Freiburg, Freiburg, Germany
| | - K. Freyler
- Department of Sport Science, University of Freiburg, Freiburg, Germany
| | - L. Jablonka
- Department of Sport Science, University of Freiburg, Freiburg, Germany
| | - R. Ritzmann
- Department of Sport Science, University of Freiburg, Freiburg, Germany
| |
Collapse
|
39
|
Bastian H, Worsch M, Huppertz A, Krause A, Schmidt WA. [Rare manifestations of axial skeleton gouty arthropathy]. Internist (Berl) 2016; 58:191-195. [PMID: 27730254 DOI: 10.1007/s00108-016-0136-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Clinical manifestations of gouty arthropathy are usually acute inflammatory arthritis, bursitis and accumulation of urate crystals in the form of tophi. Manifestations on the axial skeleton are also known and have been described but occur infrequently and for this reason play a subordinate role in the awareness of rheumatologists. With dual energy computed tomography (CT) gout tophi can be detected even in unusual regions or regions that are difficult to access for puncturing. We describe two rare cases of gouty arthropathy of the axial skeleton in a 76-year-old male patient with spinal involvement and in a 53-year-old female patient with involvement of the sacroiliac joint. In both cases the diagnosis was achieved with dual energy CT.
Collapse
Affiliation(s)
- H Bastian
- Klinik für Innere Medizin, Immanuel Krankenhaus Berlin, Standort Berlin-Buch, Berlin, Deutschland.
| | - M Worsch
- Klinik für Innere Medizin, Immanuel Krankenhaus Berlin, Standort Berlin-Buch, Berlin, Deutschland
| | - A Huppertz
- Diagnostische und Interventionelle Radiologie, Klinikum Ernst von Bergmann Potsdam, Potsdam, Deutschland
| | - A Krause
- Klinik für Innere Medizin, Immanuel Krankenhaus Berlin, Standort Berlin-Buch, Berlin, Deutschland
| | - W A Schmidt
- Klinik für Innere Medizin, Immanuel Krankenhaus Berlin, Standort Berlin-Buch, Berlin, Deutschland
| |
Collapse
|
40
|
Krause A, Nowak Z, Srbu R, Bell H. Respiratory autoresuscitation following severe acute hypoxemia in anesthetized adult rats. Respir Physiol Neurobiol 2016; 232:43-53. [DOI: 10.1016/j.resp.2016.06.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Revised: 06/28/2016] [Accepted: 06/30/2016] [Indexed: 01/16/2023]
|
41
|
Baraliakos X, Heldmann F, van den Bosch F, Burmester G, Gaston H, van der Horst-Bruinsma IE, Krause A, Schmidt R, Schneider M, Sieper J, Andermann B, van Tubergen A, Witt M, Braun J. Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction. RMD Open 2016; 2:e000272. [PMID: 27493791 PMCID: PMC4964174 DOI: 10.1136/rmdopen-2016-000272] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2016] [Revised: 04/24/2016] [Accepted: 05/03/2016] [Indexed: 01/15/2023] Open
Abstract
Objective To analyse the treatment outcome of patients with ankylosing spondylitis (AS) in the European AS infliximab cohort (EASIC) study after a total period of 8 years with specific focus on dosage and the duration of intervals between infliximab infusions. Methods EASIC included patients with AS who had received infliximab for 2 years as part of the ASSERT trial. After that period, rheumatologists were free to change the dose or the intervals of infliximab. Clinical data were status at baseline, end of ASSERT and for a total of 8 years of follow-up. Results Of the initially 71 patients with AS from EASIC, 55 patients (77.5%) had completed the 8th year of anti-tumour necrosis factor (TNF) treatment. Of those, 48 patients (87.3%) still continued on infliximab. The mean infusion interval increased slightly from 6 to 7.1±1.5 weeks, while 45.8% patients had increased the intervals up to a maximum of 12 weeks. The mean infliximab dose remained stable over time, with a minimum of 3.1 mg/kg and a maximum of 6.4 mg/kg. In patients receiving <5 mg/kg infliximab, the mean infusion interval increased to 7.0±1.2 weeks. In total, the mean cumulative dose per patient and per year decreased from 3566.30 to 2973.60 mg. Conclusions We could observe that over a follow-up of 8 years of treatment with infliximab, >85% patients still remained on the same treatment, without any major safety events. Furthermore, both the infusion intervals and also the mean infliximab dose were modestly reduced in ≥70% of the patients without the loss of clinical efficiency.
Collapse
Affiliation(s)
| | - F Heldmann
- Zeisigwaldkliniken Bethanien , Chemnitz , Germany
| | | | - G Burmester
- Charité University Medicine Berlin , Berlin , Germany
| | - H Gaston
- University of Cambridge , Cambridge , UK
| | | | - A Krause
- Immanuel Krankenhaus , Berlin , Germany
| | - R Schmidt
- Medical University Hannover , Germany
| | | | - J Sieper
- Charité Campus Benjamin Franklin , Berlin , Germany
| | - B Andermann
- Private rheumatology practice , Berlin , Germany
| | | | - M Witt
- University of Munich , Germany
| | - J Braun
- Rheumazentrum Ruhrgebiet , Herne , Germany
| |
Collapse
|
42
|
Schäfer V, Juche A, Ramiro S, Krause A, Schmidt W. FRI0393 Cut-Off Values for Intima-Media Thickness of Temporal, Facial and Axillary Arteries in Giant Cell Arteritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2760] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Baganz L, Strangfeld A, Kekow J, Bussmann A, Krause A, Stille C, Listing J, Richter A, Zink A. FRI0226 Tocilizumab Is Similarly Effective in RA Patients with No or Up To Two Prior Bdmard Failures: Results from The German Prospective Cohort Study Rabbit. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
44
|
Wojnarowska Z, Knapik J, Rams-Baron M, Jedrzejowska A, Paczkowska M, Krause A, Cielecka-Piontek J, Jaworska M, Lodowski P, Paluch M. Amorphous Protic Ionic Systems as Promising Active Pharmaceutical Ingredients: The Case of the Sumatriptan Succinate Drug. Mol Pharm 2016; 13:1111-22. [PMID: 26836258 DOI: 10.1021/acs.molpharmaceut.5b00911] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
In this article, we highlight the benefits coming from the application of amorphous protic ionic systems as active pharmaceutical ingredients (APIs). Using the case of the sumatriptan (STR) drug, we show that the conversion of nonionic API to partially ionized amorphous protic succinate salt (STR SUCC) brings a substantial improvement in apparent solubility. Since in general the disordered systems reveal a tendency to self-arrangement during storage, the dominant part of this article is dedicated to the physical stability issue of sumatriptan and its ionic counterpart. To recognize the crystallization tendency of the studied systems, the calorimetric measurements were performed. Additionally, the role of ion dynamics in spontaneous nucleation of amorphous sumatriptan succinate is discussed. The differential scanning calorimetry analysis of ionic and nonionic sumatriptan reveals many similarities in thermal properties of these APIs as well as distinct differences in their resistance against crystallization in the supercooled liquid state. To determine the long-term physical stability of STR SUCC at room temperature conditions, the time scale of structural relaxation below their glass transition temperatures is estimated. We show that in contrast to nonionic materials, τα predictions of STR SUCC are much more complex and require aging experiments.
Collapse
Affiliation(s)
- Z Wojnarowska
- Institute of Physics, University of Silesia , Uniwersytecka 4, 40-007 Katowice, Poland.,SMCEBI , 75 Pulku Piechoty 1A, 41-500 Chorzow, Poland
| | - J Knapik
- Institute of Physics, University of Silesia , Uniwersytecka 4, 40-007 Katowice, Poland.,SMCEBI , 75 Pulku Piechoty 1A, 41-500 Chorzow, Poland
| | - M Rams-Baron
- Institute of Physics, University of Silesia , Uniwersytecka 4, 40-007 Katowice, Poland.,SMCEBI , 75 Pulku Piechoty 1A, 41-500 Chorzow, Poland
| | - A Jedrzejowska
- Institute of Physics, University of Silesia , Uniwersytecka 4, 40-007 Katowice, Poland.,SMCEBI , 75 Pulku Piechoty 1A, 41-500 Chorzow, Poland
| | - M Paczkowska
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences , Grunwaldzka 6, 60-780 Poznań, Poland
| | - A Krause
- PozLab sp. z.o.o. Parkowa 2, 60-775 Poznań, Poland
| | - J Cielecka-Piontek
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences , Grunwaldzka 6, 60-780 Poznań, Poland
| | - M Jaworska
- Institute of Chemistry, Department of Theoretical Chemistry, University of Silesia , Szkolna 9, 40-006 Katowice, Poland
| | - P Lodowski
- Institute of Chemistry, Department of Theoretical Chemistry, University of Silesia , Szkolna 9, 40-006 Katowice, Poland
| | - M Paluch
- Institute of Physics, University of Silesia , Uniwersytecka 4, 40-007 Katowice, Poland.,SMCEBI , 75 Pulku Piechoty 1A, 41-500 Chorzow, Poland
| |
Collapse
|
45
|
Dutta S, Krause A, Vosberg S, Herold T, Ksienzyk B, Quintanilla-Martinez L, Tizazu B, Chopra M, Graf A, Krebs S, Blum H, Greif PA, Vetter A, Metzeler K, Rothenberg-Thurley M, Schneider MR, Dahlhoff M, Spiekermann K, Zimber-Strobl U, Wolf E, Bohlander SK. The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models. Leukemia 2015; 30:1166-76. [PMID: 26686248 DOI: 10.1038/leu.2015.349] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Revised: 11/26/2015] [Accepted: 12/03/2015] [Indexed: 11/09/2022]
Abstract
The CALM/AF10 fusion gene is found in various hematological malignancies including acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia and malignant lymphoma. We have previously identified the leukemia stem cell (LSC) in a CALM/AF10-driven murine bone marrow transplant AML model as B220+ lymphoid cells with B-cell characteristics. To identify the target cell for leukemic transformation or 'cell of origin of leukemia' (COL) in non-disturbed steady-state hematopoiesis, we inserted the CALM/AF10 fusion gene preceded by a loxP-flanked transcriptional stop cassette into the Rosa26 locus. Vav-Cre-induced panhematopoietic expression of the CALM/AF10 fusion gene led to acute leukemia with a median latency of 12 months. Mice expressing CALM/AF10 in the B-lymphoid compartment using Mb1-Cre or CD19-Cre inducer lines did not develop leukemia. Leukemias had a predominantly myeloid phenotype but showed coexpression of the B-cell marker B220, and had clonal B-cell receptor rearrangements. Using whole-exome sequencing, we identified an average of two to three additional mutations per leukemia, including activating mutations in known oncogenes such as FLT3 and PTPN11. Our results show that the COL for CALM/AF10 leukemia is a stem or early progenitor cell and not a cell of B-cell lineage with a phenotype similar to that of the LSC in CALM/AF10+ leukemia.
Collapse
Affiliation(s)
- S Dutta
- Department of Medicine III, University Hospital Grosshadern, Ludwig Maximilians-University, Munich, Germany.,Clinical Cooperative Group Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany
| | - A Krause
- Department of Small Animal Medicine, Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil
| | - S Vosberg
- Department of Medicine III, University Hospital Grosshadern, Ludwig Maximilians-University, Munich, Germany.,Clinical Cooperative Group Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany
| | - T Herold
- Department of Medicine III, University Hospital Grosshadern, Ludwig Maximilians-University, Munich, Germany.,Clinical Cooperative Group Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - B Ksienzyk
- Department of Medicine III, University Hospital Grosshadern, Ludwig Maximilians-University, Munich, Germany
| | - L Quintanilla-Martinez
- Institute for Pathology, University Hospital and Faculty of Medicine, University of Tübingen, Tübingen, Germany
| | - B Tizazu
- Department of Medicine III, University Hospital Grosshadern, Ludwig Maximilians-University, Munich, Germany.,Clinical Cooperative Group Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany
| | - M Chopra
- Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - A Graf
- Laboratory for Functional Genome Analysis, Gene Center, Ludwig Maximilians-University, Munich, Germany
| | - S Krebs
- Laboratory for Functional Genome Analysis, Gene Center, Ludwig Maximilians-University, Munich, Germany
| | - H Blum
- Laboratory for Functional Genome Analysis, Gene Center, Ludwig Maximilians-University, Munich, Germany
| | - P A Greif
- Department of Medicine III, University Hospital Grosshadern, Ludwig Maximilians-University, Munich, Germany.,Clinical Cooperative Group Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - A Vetter
- Department of Medicine III, University Hospital Grosshadern, Ludwig Maximilians-University, Munich, Germany.,Clinical Cooperative Group Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - K Metzeler
- Department of Medicine III, University Hospital Grosshadern, Ludwig Maximilians-University, Munich, Germany.,Clinical Cooperative Group Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany
| | - M Rothenberg-Thurley
- Department of Medicine III, University Hospital Grosshadern, Ludwig Maximilians-University, Munich, Germany.,Clinical Cooperative Group Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany
| | - M R Schneider
- Institute of Molecular Animal Breeding and Biotechnology, Ludwig Maximilians-University, Munich, Germany
| | - M Dahlhoff
- Institute of Molecular Animal Breeding and Biotechnology, Ludwig Maximilians-University, Munich, Germany
| | - K Spiekermann
- Department of Medicine III, University Hospital Grosshadern, Ludwig Maximilians-University, Munich, Germany.,Clinical Cooperative Group Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - U Zimber-Strobl
- Department of Gene Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany
| | - E Wolf
- Institute of Molecular Animal Breeding and Biotechnology, Ludwig Maximilians-University, Munich, Germany
| | - S K Bohlander
- Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| |
Collapse
|
46
|
Krause A, Zebunke M, Bellmann O, Mohr E, Langbein J, Puppe B. Surgical implantation and functional assessment of an invasive telemetric system to measure autonomic responses in domestic pigs. Vet J 2015; 207:140-146. [PMID: 26626089 DOI: 10.1016/j.tvjl.2015.10.050] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Revised: 10/19/2015] [Accepted: 10/24/2015] [Indexed: 10/22/2022]
Abstract
The first aim of this study was to establish a surgical procedure to implant a new telemetric device for the continuous recording of electrocardiogram (ECG) and blood pressure (BP) in freely moving pigs. A second aim was the functional assessment of cardiovascular parameters, including heart rate variability (HRV) and blood pressure variability (BPV), so that these data could be used as the basis for the objective evaluation of autonomic activity and balance in different behavioural contexts. Eleven domestic pigs (German Landrace) underwent surgery for the placement of a telemetric device. At day 15 after surgery, 512 consecutive inter-beat intervals and pressure waves were analysed using different detection methods (automatic and manually corrected) while the animals were resting or feeding, respectively. HRV and BPV were calculated. Incomplete datasets were found in four pigs due to missing ECG or BP signals. Technical and surgical issues concerning catheterisation and detachment of the negative ECG lead were continuously improved. In the remaining pigs, excellent signal quality (manually corrected data of 1%) was obtained during resting and acceptable signal quality (<10%) was obtained during feeding. Automatic triggering was sufficiently reliable to eliminate errors in BP recordings during active behaviour, but this was not the case for ECG recordings. Sympathetic arousal with accompanying vagal withdrawal during feeding was documented. The established surgical implantation and functional assessment of the telemetric system with the reliable registration of cardiovascular parameters in freely moving pigs could serve as a basis for future studies of autonomic regulation in context of stress and animal welfare.
Collapse
Affiliation(s)
- A Krause
- Institute of Behavioural Physiology, Leibniz Institute for Farm Animal Biology (FBN), D-18196 Dummerstorf, Germany
| | - M Zebunke
- Institute of Behavioural Physiology, Leibniz Institute for Farm Animal Biology (FBN), D-18196 Dummerstorf, Germany
| | - O Bellmann
- Scientific Organisation and Service, Leibniz Institute for Farm Animal Biology (FBN), D-18196 Dummerstorf, Germany
| | - E Mohr
- Animal Health and Welfare, Faculty of Agricultural and Environmental Sciences, University of Rostock, D-18059 Rostock, Germany
| | - J Langbein
- Institute of Behavioural Physiology, Leibniz Institute for Farm Animal Biology (FBN), D-18196 Dummerstorf, Germany.
| | - B Puppe
- Institute of Behavioural Physiology, Leibniz Institute for Farm Animal Biology (FBN), D-18196 Dummerstorf, Germany; Behavioural Sciences, Faculty of Agricultural and Environmental Sciences, University of Rostock, D-18059 Rostock, Germany.
| |
Collapse
|
47
|
Pereira D, Cunha V, Schmidt C, Magnus T, Krause A. Sensitization study of dogs with atopic dermatitis in the central region of Rio Grande do Sul. ARQ BRAS MED VET ZOO 2015. [DOI: 10.1590/1678-4162-8224] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Canine atopic dermatitis (CAD) is a common dermatosis, defined as a genetic-related disease which predisposes to skin inflammation and pruritus, associated to a IgE-specific response in most of cases. Clinical diagnosis may be later complemented by skin allergy and/or serological tests. The aim of these tests is to identify possible allergens in order to enable the clinicians to select candidate antigens for allergen specific immunotherapy. In the present study 58 CAD positive animals were tested. All were submitted to the intradermal test (IDT) and screened for the presence of antibodies against different antigens using ELISA. The obtained results show a high prevalence of sensitization among the tested dogs to house dust mites and to pollen ofC. dactylon. With this work it was possible to identify the main allergens involved in immunological response of dogs with CAD living in central area of Rio Grande do Sul.
Collapse
Affiliation(s)
| | | | - C. Schmidt
- Universidade Federal de Santa Maria, Brazil
| | | | - A. Krause
- Universidade Federal de Santa Maria, Brazil
| |
Collapse
|
48
|
Francies FZ, Wainstein T, De Leeneer K, Cairns A, Murdoch M, Nietz S, Cubasch H, Poppe B, Van Maerken T, Crombez B, Coene I, Kerr R, Slabbert JP, Vral A, Krause A, Baeyens A, Claes KBM. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. BMC Cancer 2015; 15:912. [PMID: 26577449 PMCID: PMC4647511 DOI: 10.1186/s12885-015-1913-6] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Accepted: 11/05/2015] [Indexed: 12/20/2022] Open
Abstract
Background Current knowledge of the aetiology of hereditary breast cancer in the four main South African population groups (black, coloured, Indian and white) is limited. Risk assessments in the black, coloured and Indian population groups are challenging because of restricted information regarding the underlying genetic contributions to inherited breast cancer in these populations. We focused this study on premenopausal patients (diagnosed with breast cancer before the age of 50; n = 78) and triple negative breast cancer (TNBC) patients (n = 30) from the four South African ethnic groups. The aim of this study was to determine the frequency and spectrum of germline mutations in BRCA1, BRCA2 and PALB2 and to evaluate the presence of the CHEK2 c.1100delC allele in these patients. Methods In total, 108 South African breast cancer patients underwent mutation screening using a Next-Generation Sequencing (NGS) approach in combination with Multiplex Ligation-dependent Probe Amplification (MLPA) to detect large rearrangements in BRCA1 and BRCA2. Results In 13 (12 %) patients a deleterious mutation in BRCA1/2 was detected, three of which were novel mutations in black patients. None of the study participants was found to have an unequivocal pathogenic mutation in PALB2. Two (white) patients tested positive for the CHEK2 c.1100delC mutation, however, one of these also carried a deleterious BRCA2 mutation. Additionally, six variants of unknown clinical significance were identified (4 in BRCA2, 2 in PALB2), all in black patients. Within the group of TNBC patients, a higher mutation frequency was obtained (23.3 %; 7/30) than in the group of patients diagnosed before the age of 50 (7.7 %; 6/78). Conclusion This study highlights the importance of evaluating germline mutations in major breast cancer genes in all of the South African population groups. This NGS study shows that mutation analysis is warranted in South African patients with triple negative and/or in premenopausal breast cancer. Electronic supplementary material The online version of this article (doi:10.1186/s12885-015-1913-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- F Z Francies
- iThemba LABS-National Research Foundation, Somerset West, South Africa. .,Department of Radiation Sciences, University of the Witwatersrand, Johannesburg, South Africa.
| | - T Wainstein
- Division of Human Genetics, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
| | - K De Leeneer
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
| | - A Cairns
- Department of Surgery, Charlotte Maxeke Johannesburg Academic Hospital and Donald Gordon Medical Centre, Johannesburg, South Africa.
| | - M Murdoch
- Department of Surgery, Charlotte Maxeke Johannesburg Academic Hospital and Donald Gordon Medical Centre, Johannesburg, South Africa.
| | - S Nietz
- Department of Surgery, Charlotte Maxeke Johannesburg Academic Hospital and Donald Gordon Medical Centre, Johannesburg, South Africa.
| | - H Cubasch
- Batho Pele Breast Unit, Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa.
| | - B Poppe
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
| | - T Van Maerken
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
| | - B Crombez
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
| | - I Coene
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
| | - R Kerr
- Division of Human Genetics, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
| | - J P Slabbert
- iThemba LABS-National Research Foundation, Somerset West, South Africa.
| | - A Vral
- Department of Basic Medical Sciences, Ghent University, Ghent, Belgium.
| | - A Krause
- Division of Human Genetics, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa. .,Division of Human Genetics, National Health Laboratory Services, Johannesburg, South Africa.
| | - A Baeyens
- iThemba LABS-National Research Foundation, Somerset West, South Africa. .,Department of Radiation Sciences, University of the Witwatersrand, Johannesburg, South Africa. .,Department of Basic Medical Sciences, Ghent University, Ghent, Belgium.
| | - K B M Claes
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
| |
Collapse
|
49
|
Hoch M, Vaclavkova A, Krause A, Strong A, Bush J, Dingemanse J, Juif PE. A Novel Gradual Up-Titration Regimen Mitigates The First-Dose Effects Of Ponesimod, A Selective S1p1 Receptor Modulator. Clin Ther 2015. [DOI: 10.1016/j.clinthera.2015.05.114] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
50
|
Baraliakos X, Heldmann F, van den Bosch F, Burmester GR, Gaston H, van der Horst-Bruinsma I, Andermann B, Krause A, Schmidt R, Schneider M, Sieper J, Witt M, Braun J. THU0234 Long-Term Efficacy of Infliximab in Patients with Ankylosing Spondylitis – Real Life Data Confirm the Potential for Dose Reduction by Stretching Infusion Intervals. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|